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The following thesis will use a variety of different gene names and protein symbols. Ac-
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for Nomenclature of Genes, Genetic Markers, Alleles, and Mutations in Mouse and Rat,
gene names are italicised with all uppercase letters when referred to Homo sapiens and
italicised with the first letter uppercase in Mus musculus. Protein names are generally all
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Zusammenfassung
Transkriptionsfaktor 4 (TCF4 ) ist unter anderem fu¨r die Entwicklung des zentralen Ner-
vensystems (ZNS), speziell im Rahmen der Neurogenese, von großer Bedeutung. Seit
2007 ist bekannt, dass die Haploinsuffizienz von TCF4 ursa¨chlich fu¨r das sogenannte
Pitt-Hopkins-Syndrom, eine schwerwiegende neurologische Entwicklungssto¨rung, ist. Das
Pitt-Hopkins-Syndrom zeichnet sich durch eine erhebliche Intelligenzminderung sowie eine
Tendenz zur Entwicklung von Epilepsien und Atmungssto¨rungen aus. Vera¨nderungen im
TCF4 -Gen werden zusa¨tzlich mit Schizophrenie und weiteren Erkrankungen aus dem
Bereich der Autismus-Spektrum-Sto¨rungen in Verbindung gebracht.
Eine ku¨rzlich vero¨ffentliche Publikation identifizierte eine u¨berraschend hohe Anzahl so-
matischer TCF4 -Mutationen in adulten Sonic hedgehog assoziierten Medulloblastomen
(SHH MBs). Medulloblastome sind hochmaligne, WHO Grad IV, Tumore der hinteren
Scha¨delgrube, die hauptsa¨chlich bei Kindern diagnostiziert werden.
Die vorliegende Arbeit bescha¨ftigt sich nun erstmalig mit der Bedeutung von TCF4 in der
Kleinhirnentwicklung und seiner Rolle in der Entstehung von SHH-assoziierten Medullo-
blastomen.
Ein Teil dieser Arbeit konzentriert sich ausschließlich auf die Rolle von TCF4 in der Klein-
hirnentwicklung. Im Rahmen von in vitro und in vivo Versuchen konnte gezeigt werden,
dass TCF4 essentiell fu¨r die Entstehung des Kleinhirns ist und ein Verlust schwerwiegende
Vera¨nderungen in Struktur und Aufbau des Kleinhirns an sich, und der verschiedenen zel-
lula¨ren Schichten im Speziellen, nach sich zieht. Ein pra¨nataler Knockout von Tcf4 in
Ma¨usen fu¨hrt zu einer Mikrozephalie, hervorgerufen durch einen signifikanten Abfall der
Proliferationsraten sowie einem signifikanten Anstieg in der Apopotoserate der Ko¨rnerzel-
len. Weiterhin zeigen die Ergebnisse dieser Arbeit, dass es durch den Verlust von Tcf4 zu
einer fehlerhaften bzw. nicht vollsta¨ndigen Migration der Ko¨rnerzellen von der externen
Ko¨rnerzellschicht in die interne Ko¨rnerzellschicht des Kleinhirns kommt. Das fu¨r diese
Arbeit neu etablierte Mausmodell des Genotyps hGFAP-cre::Tcf4fl/fl zeichnet sich durch
auffa¨llige U¨bereinstimmung mit den pha¨notypischen Charakteristika des Pitt-Hopkins-
Syndroms aus. Die vorliegende Arbeit stellt deshalb ein neues Mausmodell fu¨r das Pitt-
Hopkins-Syndrom vor, das fu¨r ausfu¨hrliche Untersuchungen des zentralnervo¨sen Pha¨no-
typs dieser Erkrankung herangezogen werden kann. Eine Besonderheit dieses Tiermodells
liegt in seinem homozygoten Tcf4 Knockout, der normalerweise lethal ist.
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Im Unterschied zu einem pra¨natalen Knockout konnte gezeigt werden, dass ein postnataler
Knockout von Tcf4 in vitro zu einem Anstieg der Proliferation von Ko¨rnerzellvorla¨ufern
fu¨hrt. Diese Ergebnisse sind ein erster Hinweis darauf, dass ein TCF4 Verlust abha¨ngig
vom Zeitpunkt des Knockouts gegenteilige Effekte erzielt und Tcf4 unterschiedliche Funk-
tionen in unterschiedlichen Phasen der ZNS-Entwicklung u¨bernimmt.
Ein zweiter Teil dieser Arbeit befasst sich mit der Bedeutung von TCF4 im Rahmen der
Entstehung von adulten SHH MBs. Die Ergebnisse einer ersten Analyse eines humanen
Datensets zeigten auf, dass das Expressionsniveau von TCF4 mRNA in SHH assoziierten
Medulloblastomen gegenu¨ber der normalen Expression im Cerebellum u¨ber alle Alters-
gruppen hinweg deutlich erho¨ht ist. Hohe Expressionslevel sind zudem mit einer besseren
Progonse, d.h. einem la¨ngeren Gesamtu¨berleben, der Erkrankung assoziiert. Eine Un-
tersuchung der Funktion von TCF4 innerhalb einer Medulloblastomzelllinie kam zu dem
Ergebnis, dass die U¨berexpression von Wildtyp-TCF4 zu einer signifikanten Verringer-
ung der Proliferationsrate der Zellen fu¨hrt und dass unterschiedliche TCF4-Mutanten die
Proliferationsrate abha¨ngig von ihrer Restfunktion beeinflussen. Insgesamt zeigen die
gewonnenen Ergebnisse, dass TCF4 in der postnatalen Entwicklung tumorsuppressive
Funktionen ausu¨bt. In vivo-Versuche in Ma¨usen, die SHH MBs entwickeln, konnten zei-
gen, dass auch hier im Rahmen eines pra¨natalen Tcf4 -Knockouts mit einem Anstieg der
Apoptoserate zu rechnen ist.
Die Experimente, die im Zusammenhang der Untersuchungen von Medulloblastomen
durchgefu¨hrt wurden, konnten demnach die zuvor aufgestellte Hypothese, dass die Funk-
tion von TCF4 zeitabha¨ngig ist, besta¨tigen. Es zeigt sich, dass ein pra¨nataler Knockout
des TCF4 Gens zu einer verringerten Profilferations- und erho¨hrten Apoptoserate fu¨hrt,
wohingegen ein postnataler Knockout im Gegenteil einen Anstieg der Proliferation von
Ko¨rnerzellen nach sich zieht.
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Abstract
Transcription factor 4 (TCF4 ) plays an important role in development of the central
nervous system (CNS), particularly in neurogenesis. In 2007, haploinsufficiency of TCF4
was found to be the underlying molecular cause of Pitt-Hopkins syndrome, a severe
neurodevelopmental disorder that leads to intellectual disability and a tendency to develop
epilepsy as well as breathing abnormalities. Furthermore, variants in TCF4 have been
associated with schizophrenia and other neurodevelopmental disorders causing autistic-
like behaviour.
Very recently, a high number of somatic TCF4 mutations were identified in adult Sonic
hedgehog associated medulloblastoma (SHH MB), a malignant tumour of the posterior
fossa, predominantly found in children.
This thesis, for the first time, investigates the role of TCF4 in the formation and growth
of medulloblastoma and the importance of TCF4 in the development of the cerebellum.
One part of this thesis focuses on the role of TCF4 during development of the cere-
bellum. Findings from in vitro and in vivo experiments show that TCF4 is crucial for the
development of the cerebellum and that its loss causes severe alterations to the anatomical
structure of the cerebellum in general and the individual cellular layers in specific. Mice
used for these experiments were of the genotype hGFAP-cre::Tcf4fl/fl whose phenotypical
features were shown to match those of patients with Pitt-Hopkins syndrome. A prenatal
knockout of Tcf4 in mice leads to a significant decrease in proliferation and a significant
increase in apoptosis of granule cells, leading to growth retardation and microcephaly.
The results presented in the present work provide evidence for migratory deficits in gran-
ule cells caused by a knockout of Tcf4, as cells are no longer able to migrate from the
external granular layer into the internal granular layer. Taken all these findings together,
this work proposes a new mouse model for Pitt-Hopkins syndrome that can be used to
investigate this disorder in more detail with specific focus on changes to the nervous
system. Furthermore, this animal model is currently the only model that is viable as a
homozygous knockout.
In contrast to a prenatal knockout, a postnatal knockout of Tcf4 in vitro is shown to
be responsible for an increase in proliferation in granule precursor cells, indicating that
TCF4 might have opposing effects depending on its time of knockout.
ix
The second part of this thesis aimed at understanding the role of TCF4 in development
of adult SHH MBs. The analysis of a human dataset was able to show that mRNA levels
of TCF4 are highly increased in SHH MBs for all age groups and that high TCF4 levels
are associated with a favourable outcome. An investigation of the function of TCF4 in a
medulloblastoma cell line showed that overexpression of wild-type TCF4 causes a signific-
ant decrease in proliferation and that different TCF4 mutants alter proliferation rates in
accordance with their left-over functionality. These findings provide evidence that TCF4
acts as a tumour suppressor in postnatal development. In vivo experiments in mice devel-
oping SHH-associated medulloblastoma showed that a loss of Tcf4 results in an increase
in apoptosis when the knockout occurs prenatally.
Finally, the experiments carried out in the tumorous environment confirmed the ini-
tial hypothesis that the function of TCF4 is time-sensitive. A prenatal knockout of the
TCF4 gene therefore causes a decrease in proliferation and increase of apoptosis, whereas
a postnatal knockout on the opposite leads to an increase in proliferation.
x
Contents
Eidesstattliche Versicherung iv
Acknowledgements v
Zusammenfassung vii
Abstract ix
List of Figures xiv
List of Tables xvi
Abbreviations xvii
Gene names and symbols xix
1 Introduction 1
1.1 Transcription factor 4 (TCF4 ) . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 TCF4 structure and function . . . . . . . . . . . . . . . . . . . . . 2
1.1.2 TCF4 during brain development . . . . . . . . . . . . . . . . . . . 4
1.1.3 TCF4 animal models . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.1.4 TCF4 -associated diseases . . . . . . . . . . . . . . . . . . . . . . . 5
1.2 Pitt-Hopkins syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.2.1 Cause of Pitt-Hopkins syndrome . . . . . . . . . . . . . . . . . . . . 6
1.2.2 Clinical features of PTHS . . . . . . . . . . . . . . . . . . . . . . . 7
1.2.3 Diagnosis, treatment, and prognosis of PTHS . . . . . . . . . . . . 8
1.2.4 Mutational spectrum of PTHS . . . . . . . . . . . . . . . . . . . . . 9
1.2.5 Pitt-Hopkins animal models . . . . . . . . . . . . . . . . . . . . . . 9
1.3 Cerebellum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.3.1 Structure and function of the cerebellum . . . . . . . . . . . . . . . 10
1.3.2 Development of the cerebellum . . . . . . . . . . . . . . . . . . . . 12
xi
Contents
1.4 Medulloblastoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.4.1 Medulloblastoma subgroups . . . . . . . . . . . . . . . . . . . . . . 13
1.4.2 SHH signalling pathway . . . . . . . . . . . . . . . . . . . . . . . . 15
1.4.3 Origins of medulloblastoma . . . . . . . . . . . . . . . . . . . . . . 17
1.4.4 Symptoms, diagnosis, and current treatment strategies of MB . . . 18
1.4.5 Medulloblastoma mouse models . . . . . . . . . . . . . . . . . . . . 19
2 Aims 20
3 Results 21
3.1 Human data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
3.1.1 TCF4 expression levels in medulloblastoma . . . . . . . . . . . . . 21
3.1.2 Analysis of long-term survival of MB patients . . . . . . . . . . . . 22
3.2 Investigation of known TCF4 mutations . . . . . . . . . . . . . . . . . . . 24
3.2.1 TCF4 mutations in MB . . . . . . . . . . . . . . . . . . . . . . . . 24
3.2.2 Influence of WT TCF4 and TCF4 mutants on proliferation in a MB
cell line . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.3 Establishing the mouse models . . . . . . . . . . . . . . . . . . . . . . . . . 28
3.4 In vitro loss of Tcf4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.5 In vivo loss of Tcf4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.5.1 Macro-anatomical aspects . . . . . . . . . . . . . . . . . . . . . . . 31
3.5.2 Micro-anatomical aspects . . . . . . . . . . . . . . . . . . . . . . . . 35
3.5.3 Mouse model and Pitt-Hopkins syndrome . . . . . . . . . . . . . . . 43
3.6 In vivo loss of Tcf4 in SHH MB . . . . . . . . . . . . . . . . . . . . . . . . 45
3.6.1 Prenatal loss of Tcf4 . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.6.2 Postnatal loss of Tcf4 . . . . . . . . . . . . . . . . . . . . . . . . . 48
4 Discussion 50
4.1 Importance of TCF4 in cerebellum development . . . . . . . . . . . . . . . 51
4.1.1 Anatomical alterations and correlations to PTHS in Tcf4 -deficient
mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
4.1.2 Migratory deficits in the cerebellar cortex of Tcf4 -deficient mice . . 53
4.2 Comparison of the PTHS mouse models . . . . . . . . . . . . . . . . . . . 54
4.3 Role of TCF4 in SHH medulloblastoma . . . . . . . . . . . . . . . . . . . . 57
4.4 Prenatal versus postnatal TCF4 knockout . . . . . . . . . . . . . . . . . . 58
5 Conclusions 60
xii
Contents
6 Perspectives 61
7 Material and Methods 63
7.1 Material . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
7.1.1 Appliances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
7.1.2 Software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
7.1.3 Chemicals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
7.1.4 Kits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
7.1.5 Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
7.1.6 Plasmids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
7.1.7 Mouse strains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
7.1.8 Self-made buffers and media . . . . . . . . . . . . . . . . . . . . . . 69
7.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
7.2.1 General molecular biological methods . . . . . . . . . . . . . . . . . 71
7.2.2 Cell culture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
7.2.3 Mouse experiments . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
7.2.4 Histological methods . . . . . . . . . . . . . . . . . . . . . . . . . . 83
7.2.5 Human data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
7.2.6 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
8 Bibliography 87
9 Appendix 105
xiii
List of Figures
1 Simplified structure of TCF4-B− . . . . . . . . . . . . . . . . . . . . . . . . 2
2 Facial features of patients with PTHS . . . . . . . . . . . . . . . . . . . . . 7
3 Overview of the cerebellar layers . . . . . . . . . . . . . . . . . . . . . . . . 11
4 Overview of MB subgroups . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
5 SHH pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
6 TCF4 mRNA expression in MB . . . . . . . . . . . . . . . . . . . . . . . . 22
7 Kaplan-Meier plots for patients with SHH MB . . . . . . . . . . . . . . . . 23
8 Structure of TCF4 protein sequence highlighting known TCF4 mutations . 25
9 WT TCF4 decreases proliferation of DAOY cells significantly . . . . . . . . 27
10 Tcf4 knockout increases proliferation of CGNP cells . . . . . . . . . . . . . 30
11 In vivo loss of Tcf4 causes growth retardation in mice . . . . . . . . . . . . 32
12 Tcf4 knockout in mice leads to microcephaly . . . . . . . . . . . . . . . . . 33
13 Loss of Tcf4 causes decrease in whole body and brain weights . . . . . . . 34
14 Hippocampus of adult mice is altered due to Tcf4 knockout . . . . . . . . 35
15 TCF4 expression in the mouse cerebellum . . . . . . . . . . . . . . . . . . 37
16 Loss of Tcf4 alters anatomical structure of the cerebellum . . . . . . . . . 38
17 Influence of Tcf4 on proliferation and apoptosis of granule cells . . . . . . 40
18 Loss of Tcf4 causes migratory deficits in granule cells . . . . . . . . . . . . 42
19 MRI of a patient with PTHS and aged-matched control . . . . . . . . . . . 44
20 Prenatal loss of Tcf4 does not alter survival rates in SHH MB . . . . . . . 46
21 Prenatal knockout of Tcf4 in SHH MB increases apoptosis rates but does
not influence proliferation . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
22 Postnatal Tcf4 knockout does not alter survival in SHH MB . . . . . . . . 48
23 Postnatal knockout of Tcf4 in SHH MB . . . . . . . . . . . . . . . . . . . 49
24 Site directed mutagenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
25 Example DNA and protein sequence of TCF4 mutant . . . . . . . . . . . . 74
xiv
List of Figures
26 TCF4 interaction network . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
27 TCF4 mRNA levels in SHH MB and normal brain tissue . . . . . . . . . . 106
28 Summary of sequencing data from Kool et al. (2014) . . . . . . . . . . . . 107
29 Math1-cre::Tcf4fl/fl mice at P22 . . . . . . . . . . . . . . . . . . . . . . . . 107
30 Apoptosis rates in hGFAP-cre::Tcf4fl/fl mice on P14 . . . . . . . . . . . . 108
31 MRI of a 19-months old girl with PTHS . . . . . . . . . . . . . . . . . . . 108
32 Human TCF4 protein sequence . . . . . . . . . . . . . . . . . . . . . . . . 109
xv
List of Tables
1 Nomenclature for gene and protein symbols . . . . . . . . . . . . . . . . . xix
2 Somatic TCF4 mutations identified in SHH MBs . . . . . . . . . . . . . . . 24
3 Comparison of the PTHS mouse models . . . . . . . . . . . . . . . . . . . 55
4 Primer sequences used for site directed mutagenesis . . . . . . . . . . . . . 73
5 Plasmids used for transfection of DAOY cells . . . . . . . . . . . . . . . . . 76
6 Primers used for genotyping . . . . . . . . . . . . . . . . . . . . . . . . . . 81
7 PCR programmes used for genotyping . . . . . . . . . . . . . . . . . . . . 81
8 Antibodies for IHC of embedded tissues . . . . . . . . . . . . . . . . . . . . 84
9 Antibodies for immunofluorescence . . . . . . . . . . . . . . . . . . . . . . 85
10 P-values for brain weights of hGFAP-cre::Tcf4+/+ mice . . . . . . . . . . . 110
xvi
Abbreviations
AA Amino Acid
AD Activation Domain
ATCC American Type Culture Collection
Atoh1 Atonal bHLH Transcription Factor 1
BCA Bicinchoninic Acid
bHLH Basix Helix-loop-helix
BrdU Bromodeoxyuridine
C Carnegie stage
CASP3 Caspase 3
CGH Comparative Genomic Hybridisation
CGNP Cerebellar Granular Neuron Precursor
CNS Central Nervous System
CSF Cerebrospinal Fluid
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
DAPI 4’,6-diamidino-2-phenylindole
DMEM Dulbecco’s Modified Eagle’s Medium
DMSO Dimethyl Sulfoxide
DNA Deoxyribonucleic Acid
E Embryonic day
EDTA Ethylenediaminetetraacetic Acid
EGL Extrenal Granular Layer
FCS Fetal Calf Serum
FRT Flippase Recognition Target
GCP Granule cell progenitor
GFP Green Fluorescent Protein
GI Gastrointestinal
GLI Glioma-associated oncogene
HBS HEPES Buffered Saline
HBSS Hanks’ Balanced Salt Solution
HCl Hydrogen Chloride
HDAC Histone Deacetylase
H&E Hematoxylin and Eosin
HEK Human Embryonic Kidney cells
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
Het Heterozygous
hGFAP Human Glial Fibrillary Acidic Protein
Hom Homozygous
ICH Immunohistochemistry
ID Intellectual Disability
IF Immunofluorescence
IgG Immunglobulin G
IGL Internal Granular Layer
xvii
ITF Immunoglobulin Transcription Factor
IRES Internal Ribosome Entry Site
KO Knockout
LB Lysogeny Broth
LRL Lower Rhombic Lip
MB Medulloblastoma
ML Molecular Layer
MRI Magnetic Resonance Imaging
NLS Nuclear Localisation Sequence
OMIM Online Mendelian Inheritance in Man
P Post partum (Post-natal day)
PAX6 Paired Box Protein 6
PBS Phosphate-buffered Saline
PCL Purkinje Cell Layer
PCR Polymerase Chain Reaction
PFA Paraformaldehyde
PGR Postnatal Growth Retardation
PLO Poly-L ornithine
PHH3 Phosphohistone H3
PTCH Patched
PTHS Pitt-Hopkins syndrome
RL Rhombic Lip
RNA Ribonucleic Acid
RT Room Temperature
SD Standard Deviation
SHH Sonic hedgehog
shRNA Short hairpin RNA
SMO Smoothened
SNP Single-nucleotide Polymorphism
SOC Super Optimal broth with Catabolite repression
SUFU Suppressor of fused homolog
TCF Transcription factor
TCF4 Transcription factor 4
TCF7L2 Transcription factor 7 like 2
TE Tris-EDTA
URL Upper Rhombic Lip
VZ Ventricular Zone
WT Wild type
YFP Yellow Fluorescent Protein
xviii
Gene names and symbols
Gene names and protein symbols are written according to the HGNC Guidelines for
Human Gene Nomenclature (HGNC, 2018) and the MGI Guidelines for Nomenclature
of Genes, Genetic Markers, Alleles, and Mutations in Mouse and Rat (MGI-Guidelines,
2018). Messenger RNA and complementary DNA in humans use the same format as the
corresponding genomic DNA.
Table 1: Nomenclature for gene and protein symbols exemplified by TCF4.
Species Gene symbol Protein symbol
Homo sapiens TCF4 TCF4
Mus musculus Tcf4 TCF4
Danio rerio tcf4 Tcf4
xix
xx
1 Introduction
1.1 Transcription factor 4 (TCF4 )
Transcription factor 4 (TCF4 ) is a member of the superfamily of basic helix-loop-helix
(bHLH) transcription factors. This family has a highly conserved role in the specification
and differentiation of several cell types, such as neurons and cells of the immune sys-
tem during development (Forrest et al., 2012). TCF4 is a member of the class A bHLH
factors, also known as E-proteins, with the others being E2A (isoforms E12, E47) and
HEB (Murre, 2005). E-proteins are widely expressed during nervous system development
and they activate transcription through binding to so-called Ephrussi DNA box sequences
(E-boxes) (Peippo and Ignatius, 2011). Binding to these E-boxes occurs as homo- or het-
erodimers, hence, the function of TCF4 is influenced by its dimerisation partner (Sepp
et al., 2011).
Due to its role in the development of multiple cell types, TCF4 was discovered in differ-
ent contexts. TCF4 is thus alternatively known by the names SEF2, ITF2, E2-2, ME2,
and others (Sweatt, 2013). TCF4 is not to be confused with the T cell factor 4, widely
referred to as Tcf4, whose actual gene name is transcription factor 7-like 2 (TCF7L2 )
(Forrest et al., 2012). When talking about TCF4, it should be specified which TCF4 is
discussed, especially since a connection between T cell factor 4, a downstream effector of
the β-catenin/WNT signalling pathway, and the actual TCF4 has been made; with TCF4
being a downstream target of the β-catenin/WNT/TCF pathway itself (de Pontual et al.,
2009).
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1.1.1 TCF4 structure and function
TCF4 is located on chromosome 18q21.2; it spans a length of 414 kb (Homo sapiens
Annotation Release 108, GRCh38.p7) and consists of 21 exons, with exon 21 not being
translated (de Pontual et al., 2009).1 18 N-terminally distinct TCF4 isoforms (TCF4-A to
-R) have been described to date (Sepp et al., 2011). The so-called full-length TCF4, that
is isoform TCF4-B+ and TCF4-B−, consists of 671 and 667 amino acids (AA) respectively
(Forrest et al., 2014). This full-length version of TCF4 exhibits, like other E-proteins,
two activation domains - AD1 and AD2 - and a nuclear localisation signal (NLS) (Fig. 1).
AD1 and AD2 are responsible for transcriptional activity, whereas the NLS mediates the
import into the nucleus (Forrest et al., 2014). Regardless of their different N-terminal
sequence, all TCF4 isoforms contain the AD2 (exons 14-16) and the bHLH domain (exon
19) (Sepp et al., 2011). For TCF4 to fully function, it needs to dimerise. The bHLH motif
is necessary for dimerisation and is also required for DNA binding. TCF4 can operate as
a homo- or heterodimer (Sepp et al., 2012), and depending on its dimerisation partner,
TCF4 can function as a transcriptional activator or suppressor (Skerjanc et al., 1996;
Flora et al., 2007).
Figure 1: Simplified structure of the TCF4-B− protein sequence. 667 amino
acids sequence of TCF4 isoform TCF4-B− (UniProtKB - P15884) which contains exons 3-20.
The functional domains are highlighted in different colours. AD1 and AD2 are the activation
domains (purple and green). NLS is the nuclear localization signal, responsible for the subcellular
localization of TCF4 (light blue). The basic helix loop helix domain (bHLH) is necessary for
dimerisation (turquoise). Exons 3 to 20 are marked and scaled according to their actual length.
The roles of the E-proteins in mammals overlap in many ways, so it can be difficult to
decipher the exact function of the different E-proteins (Sepp et al., 2011). Nevertheless,
TCF4 has been found to be involved in a variety of processes. For example, TCF4 is
necessary for the regulation of neurogenesis (Flora et al., 2007), lymphogenesis (Cisse
et al., 2008), myogenesis (Skerjanc et al., 1996), melanogenesis (Furumura et al., 2001),
and epithelial to mesenchymal transition (Herbst et al., 2009a; Sobrado et al., 2009).
1Sepp et al. (2011) showed that TCF4 consists of 41 exons in total, 21 of whom are 5′ initial exons
that are interspersed with exons 1-9. These exons are followed by the constitutive exons 10-20. TCF4
contains only one 3′ terminal exon, exon 21, which is non-coding. The different transcripts give rise to 18
N-terminally distinct isoforms, however, more transcripts exist due to alternate splicing. All transcripts
contain the AD2 and the bHLH domain which is encoded by exon 19 (Kharbanda et al., 2016).
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More precisely, in lymphogenesis TCF4 is responsible for the regulation of development
of B-, T-, and plasmacytoid dendritic cells (Zhuang et al., 1996; Bergqvist et al., 2000;
Cisse et al., 2008).
Mice lacking TCF4 do not survive postnatally (Flora et al., 2007), indicating how crucial
this protein is. Its heterodimerisation with other bHLH transcription factors is essential
for the development of the nervous system (Sepp et al., 2011). Activation or suppression
of transcription by TCF4 is mediated through the regulation of histone acetyltransferases
which remodel chromatin (Massari et al., 1999; Zhang et al., 2004). Just recently, the
regulation of gene transcription in the CNS through TCF4 has been proposed as an
”underlying process in language comprehension, production, and recall” (Kennedy et al.,
2016). Jung et al. (2018) see the role of TCF4 in ”the development and plasticity of
cortical and hippocampal neurons”.
A study carried out by Forrest et al. (2017), investigating TCF4 binding sites, furthermore
concluded that TCF4 is involved in the regulation of a large number of genes, comprising
risk loci for schizophrenia and neurodevelopmental disorders in general. Moreover, Moen
et al. (2017) build a protein interaction network in neural stem cells, identifying inter-
action partners of TCF4 by mass spectrometry. Using this interaction network (Fig. 26,
Appendix), the group was able to visualise that TCF4 interacts with several genes associ-
ated with and involved in intellectual disability, schizophrenia, and the autism-spectrum
disorder.
Regarding the impact of TCF4 on tumour growth and progression, opposing functions
have been proposed by different research groups. TCF4 has previously been described
as a tumour suppressor (Herbst et al., 2009b; Brandl et al., 2015), other findings suggest
TCF4 exhibits oncogenic potential (Kolligs et al., 2002; Mologni et al., 2010; Appaiah
et al., 2014). Very recently, the loss of TCF4 was shown to lead to chemoresistance in
cancer (de Garibay et al., 2018).
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1.1.2 TCF4 during brain development
The importance of TCF4 for neurodevelopment is highlighted by its wide expression dur-
ing various prenatal and postnatal stages. Soosaar et al. (1994) were the first to map the
expression of TCF4 during brain development in mice. In general, TCF4 expression was
found to be at its maximum during embryonic development. On embryonic day (E) 12,
TCF4 was detected in the cortex, the cerebellum, the pons, the medulla oblongata, and
the spinal cord. From E18 onwards until adult stages, high TCF4 levels were found in
pyramidal cells of the hippocampal layers CA1-CA4 and the granule cells of the dentate
gyrus. As for the cerebellar granule and Purkinje cells, TCF4 was expressed during all
stages. Overall, TCF4 expression was detected in proliferative zones during the develop-
ment and in areas of neuroplasticity in the adult brain, i.e. hippocampus, cerebellum,
neuroepithelium, and neocortex (Soosaar et al., 1994). Similar, de Pontual et al. (2009)
collected embryos from terminated pregnancies and scanned them for TCF4 expression.
The authors observed that from Carnegie stage (C) 13 (28-32 days post fertilisation) on-
ward, TCF4 was highly expressed throughout the CNS.
In the adult CNS, TCF4 can be detected in the cerebral cortex, the Purkinje cell and
granule cell layers of the cerebellum, the olfactory neuroepithelium, pyramidal cells of the
hippocampal layers CA1-CA4, and the granule cells of the dentate gyrus (Soosaar et al.,
1994).
1.1.3 TCF4 animal models
Animal models are widely used to investigate the function of different genes, proteins,
and pathways and are a useful tool to better understand the molecular basis of disease
and to test new treatment strategies. A couple of animal models to study TCF4 have
been described so far. Apart from several mouse models, a Danio rerio (zebra fish) and
Drosophila melanogaster model are also available.
One of the earliest genetically engineered TCF4 mouse models exhibits a ’traditional’
heterozygous Tcf4 knockout (Tcf4tm1Zhu, transcription factor 4; targeted mutation 1,
Yuan Zhuang, MGI ID: MGI:2387399) and is available from the Jackson Laboratories
(Zhuang et al., 1996). In this transgenic mouse model, the bHLH domain of Tcf4 has
been cut out by recombination (Zhuang et al., 1996). Mice homozygous for this knockout
barely survive the first postnatal week, hence, a homozygous knockout is lethal (Zhuang
et al., 1996; Flora et al., 2007). Furthermore, two conditional knockout mice have been
published (Bergqvist et al., 2000; Skarnes et al., 2011).
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One floxed Tcf4 allele was generated by Skarnes et al. (2011). Its precise description
is Tcf4tm1a(EUCOMM)Wtsi (MGI ID: MGI:4432303), which stands for ’transcription factor
4; targeted mutation 1a, Wellcome Trust Sanger Institute’ and it is available through the
EMMA mouse repository. The mouse is also referred to as Tcf4LacZ , since the inserted
cassette is composed of a flippase recognition target (FRT ) flanked lacZ/neomycin se-
quence followed by a loxP site. This mouse model can therefore be used with the Cre-lox
and the FLP-FRT system (Schnu¨tgen et al., 2005). A second floxed allel of Tcf4 was
generated by Bergqvist et al. (2000) in the laboratory of Dan Holmberg. It is referred to
as Tcf4tm1Hmb (MGI ID: MGI:3036170), which stands for ’transcription factor 4; targeted
mutation 1, Dan Holmberg’. Here, the exons encoding for the bHLH and the C-terminal
domains have been flanked by loxP sites (Sweatt, 2013). These mice will be referred to as
Tcf4fl/fl in this work. Furthermore, Rannals et al. (2016a) generated a Tcf4 knockdown
rat using short hairpin RNA (shRNA) as well as a Tcf4 knockout rat using the CRISPR-
Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated
protein 9) system.
In addition to these knockouts, Brzozka et al. (2010) generated a mouse model moder-
ately overexpressing Tcf4 postnatally (Tcf4tg), which has been used to investigate schizo-
phrenia and the function of Tcf4 in the adult brain.
Besides the described mammalian models, a tcf4 zebra fish model has been published
(Brockschmidt et al., 2011). Tcf4 was knocked down through the injection of morpholino
antisense oligonucleotides into zebra fish embryos. The model was created to study Pitt-
Hopkins syndrome (see Section 1.2) in zebra fish and was able to show that reduction
of tcf4 delays the development of the brain. Tamberg et al. (2015) introduced another
animal model using Drosophila melanogaster. They generated flies carrying Pitt-Hopkins
syndrome-associated mutations in the TCF4 homolog daughterless.
1.1.4 TCF4 -associated diseases
To date, TCF4 has been associated with several distinct diseases. In 2007, mutations
in TCF4 were found to be the cause of the neurodevelopmental disorder Pitt-Hopkins
syndrome (see Section 1.2) (Amiel et al., 2007; Zweier et al., 2007). TCF4 has further
been linked to other neurodevelopmental disorders: hemizygosity of TCF4 has been found
to increase the risk of autistic-like behaviour in patients with 18q deletions (O’Donnell
et al., 2010; Hasi et al., 2011), and TCF4 was identified as a significant schizophrenia
susceptibility gene (Brzozka et al., 2010).
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Single-nulceotide polymorphisms (SNPs) in TCF4 are also associated with Fuchs corneal
dystrophy, an autosomal dominant inherited disease that severely affects vision (Baratz
et al., 2010; Li et al., 2011). Moreover, Kool et al. (2014) were the first to describe a
series of somatic TCF4 mutations in cancer (see Chapter 2, p. 20). TCF4 has been
suspected to increase the susceptibility to develop cancer before, but only rare cases have
been reported (de Pontual et al., 2009).
1.2 Pitt-Hopkins syndrome
1.2.1 Cause of Pitt-Hopkins syndrome
De novo haploinsufficiency of TCF4 causes Pitt-Hopkins syndrome (PTHS, OMIM ID
# 610954), a rare neurodevelopmental disorder (Amiel et al., 2007; Zweier et al., 2007;
Sweatt, 2013).
The syndrome was first reported by David Pitt and Ian Hopkins, a paediatrician and
a paediatric neurologist, after following two unrelated cases of children with breathing
abnormalities and unique facial features (Pitt and Hopkins, 1978). Main characteristics
of the syndrome include severe intellectual disability (ID), typical facial gestalt, stereo-
typic movements, a tendency to develop epilepsy, and breathing abnormalities (Peippo
and Ignatius, 2011).
The molecular basis of PTHS was described in 2007, when two separate groups identified
microdeletions at chromosomal location 18q21.2 in PTHS patients which subsequently led
to the finding that haploinsufficiency of TCF4 is the underlying cause of the syndrome
(Amiel et al., 2007; Zweier et al., 2007). PTHS is an autosomal dominant disorder. How-
ever, only a few cases have been published in which a child inherited the syndrome from
a mosaic parent and there are no known cases of patients with PTHS having children
themselves (de Pontual et al., 2009; Kousoulidou et al., 2013). The prevalence of children
suffering from PTHS is hard to determine as there are only around 500 reported cases
worldwide. Rosenfeld et al. (2009) estimated the frequency of TCF4 deletions that cause
PTHS to 1/34,000 - 1/41,000, not accounting for point mutations that also cause PTHS.
The actual prevalence of PTHS amongst the population must therefore be higher. PTHS
occurs in a 1:1 ratio in males and females and there is no indication for preference of
ethnicities (Marangi et al., 2011).
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1.2.2 Clinical features of PTHS
Patients with Pitt-Hopkins syndrome exhibit a set of unique symptoms. As seen in
Fig. 2, facial features include ”the deep-set eyes, broad and beaked nasal bridge with down-
turned, pointed nasal tip, and flaring nostrils; the wide mouth with widely spaced teeth,
and Cupid-bowed and everted lower lip; the mildly cup-shaped, fleshy ears; as well as
increased coarsening of the facial features with age” (Peippo and Ignatius, 2011).
Figure 2: Facial features of patients with PTHS. Figure taken from the original
publication by Zweier et al. (2007)2. The pictures illustrate the typical facial gestalt of PTHS
patients with their deep-set eyes, as well as the distinct nasal features. Other characteristics
include a broad and beaked bride, flaring nostrils, and a pointed nasal tip. The mouth is wide
and the teeth are widely spaced (Peippo and Ignatius, 2011).
2Reprinted from The American Journal of Human Genetics, 80(5), Christiane Zweier, Maarit M.
Peippo, Juliane Hoyer, Se´rgio Sousa, Armand Bottani, Jill Clayton-Smith, William Reardon, Jorge
Saraiva, Alexandra Cabral, Ina Go¨hring, Koen Devriendt, Thomy de Ravel, Emilia K. Bijlsma, Raoul
C.M. Hennekam, Alfredo Orrico et al., Haploinsufficiency of TCF4 Causes Syndromal Mental Retard-
ation with Intermittent Hyperventilation (Pitt-Hopkins Syndrome), 994-1001, Copyright (2007), with
permission from Elsevier.
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The distinct facial gestalt normally becomes recognisable around three years of age. Post-
natal growth retardation is common, and about 60 % of the patients show postnatal
microcephaly (Peippo and Ignatius, 2011; Marangi and Zollino, 2015). One of the main
clinical features is the intellectual disability; illustrated by the fact that patients fail to
reach developmental milestones beyond the age of 12 months (Hasi et al., 2011). These
children exhibit a severe impairment of speech; with most patients being limited to a few
words only (Peippo and Ignatius, 2011). Children may also present with a happy dispos-
ition or autistic behaviour (Rosenfeld et al., 2009; O’Donnell et al., 2010). Furthermore,
the majority of patients do not learn how to walk independently and if, walking is atactic
and unsteady (Peippo and Ignatius, 2011). Generally, patients suffer from hypotonia
(Sweatt, 2013).
Children with PTHS present with stereotypical movements of the hands and sometimes of
their head. Over 40 % of cases develop epilepsy with an usual onset before school age and
more than half of patients show breathing abnormalities such as breath-holding cyanosis
and paroxysms of hyperventilation (Peippo and Ignatius, 2011). Moreover, patients often
present with symptoms in other systems, e.g. gastrointestinal disorders (mostly constip-
ation) or myopia (Peippo and Ignatius, 2011; Grubiˇsic´ et al., 2015).
1.2.3 Diagnosis, treatment, and prognosis of PTHS
Diagnosis of PTHS is based on the stereotypic clinical features and the molecular con-
firmation, typically done using array-comparative genomic hybridisation (CGH) to detect
deletions that often cause PTHS, i.e. encompass TCF4. Whalen et al. (2012) proposed
a ’Clinical Diagnostic Score’ to help decide when a TCF4 screening is indicated. How-
ever, international diagnosis criteria have not yet been established (de Winter et al., 2016).
Treatment for patients with PTHS has mainly been focused on the treatment of symptoms
such as the epilepsy and breathing abnormalities. Several single-case studies have been
published making suggestions regarding the therapeutic options for treating these complic-
ations (Gaffney and McNally, 2015; Aquino et al., 2017; Casey et al., 2017). Presently,
several research groups are looking into new treatment strategies to tackle the whole
syndrome. For example, Kennedy et al. (2016) recently proposed histone deacetylase 2
(HDAC2) inhibitors as a potential treatment after showing that HDAC inhibition is able
to rescue learning and memory deficits in PTHS mice (Kennedy et al., 2016). Further-
more, Rannals et al. (2016b) suggested the ion channel SCN10a as a potential therapeutic
target for PTHS, since haploinsufficiency of TCF4 leads to its ectopic expression.
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Although Hasi et al. (2011) have suggested PTHS patients have an increased risk of death,
the actual life expectancy of patients suffering from Pitt-Hopkins syndrome is still un-
known and the cause of death remains questionable. Several cases have been reported in
which PTHS patients died due to their breathing problems (Zweier et al., 2007; Peippo
and Ignatius, 2011).
1.2.4 Mutational spectrum of PTHS
Over a hundred different TCF4 mutations causing PTHS have been described so far, with
the mutational spectrum including a variety of mutations, e.g. chromosomal deletions,
partial gene deletions, frame-shift mutations, splice site mutations, missense mutations,
and nonsense mutations. TCF4 abnormalities seen in PTHS patients are intragenic or
perigenic and deletions range from <100 kb to 12 Mb in size (Peippo and Ignatius, 2011).
Most intragenic mutations create stop codons or alter the conserved bHLH domain of the
protein (Rosenfeld et al., 2009). The identified mutations are mostly private mutations
and only a few have been found in more than one patient (Sepp et al., 2012; Whalen et al.,
2012). TCF4 mutations can generally be found throughout the gene (Sepp et al., 2012),
however, at least one mutational hotspots was identified (Whalen et al., 2012). de Pontual
et al. (2009) initially declared a mutational hotspot in the bHLH domain, which was later
verified by Whalen et al. (2012), who came to the conclusion that mutations cluster in
exon 19, where 25 % (28/110) of total mutations in their cohort were located.
Moreover, Sepp et al. (2012) proposed that symptoms present in PTHS patients vary
depending on the site and the kind of mutation. Interestingly, apart from haploinsuffi-
ciency of TCF4 caused by deletions, some of the known mutations will still lead to the
expression of a mutant TCF4 protein, which can cause dominant-negative effects, thus
generating the PTHS phenotype in these cases (Sepp et al., 2012). There are also dele-
tions encompassing the 18q locus and mutations within TCF4 that are reported to not
cause Pitt-Hopkins syndrome (Kalscheuer et al., 2008; Soileau et al., 2015; Kharbanda
et al., 2016; Mary et al., 2018).
1.2.5 Pitt-Hopkins animal models
To better understand Pitt-Hopkins syndrome, its symptoms, clinical appearance and their
molecular causes, the establishment of a suitable animal models to study the disease is
essential. Kennedy et al. (2016) proposed the Tcf4+/− mouse, originally published by
Zhuang et al. (1996), as a suitable mouse system to model Pitt-Hopkins syndrome (see
Section 1.1.3).
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Kennedy et al. (2016) used these mice to asses behavioural and learning disabilities and
concluded, that the mice mimic PTHS in this respect. In a separate effort, Grubiˇsic´
et al. (2015) investigated the Tcf4+/− mouse in relation to the common gastrointestinal
disorders (GI disorders) and found that the mice indeed exhibit GI abnormalities seen in
PTHS patients.
As mentioned before, another PTHS model has recently been published by Rannals et al.
(2016b) who knocked down Tcf4 with two different shRNA molecules in rat prefrontal
neurons. They also created a Tcf4 knockout rat using the CRISPR/Cas9-system (Ran-
nals et al., 2016a).
In early 2018, five more mouse models to research Pitt-Hopkins syndrome were published
(Jung et al., 2018; Thaxton et al., 2018). Jung et al. (2018) assessed the previously pub-
lished Tcf4LacZ mouse, originally generated by Skarnes et al. (2011), for its use to model
PTHS. They examined a solely heterozygous knockout of Tcf4, describing that these mice
show a CNS phenotype similar to PTHS as well as a microcephaly. Thaxton et al. (2018)
used the Tcf4fl/fl mouse and created two different conditional knockouts expressing the
Cre recombinase under the Actin promoter and the Nestin promoter respectively. Addi-
tionally, Thaxton et al. (2018) generated two more mice introducing mutations that had
previously been described in PTHS, the Tcf4R579W mouse and Tcf4∆574−579 mouse which
both exhibited characteristic features of PTHS (see Section 4.2 on p. 54 for comparison
of PTHS mouse models).
Apart from these mammalian animal models, another model was generated using Droso-
phila melanogaster producing different fly strains that exhibit several of the known TCF4
mutations (Tamberg et al., 2015).
1.3 Cerebellum
1.3.1 Structure and function of the cerebellum
The cerebellum, colloquially known as the ’little brain’, resides in the posterior cranial
fossa and is part of the hindbrain of all vertebrates (Trepel, 2009). It is located inferior to
the occipital and temporal lobes, separated from these lobes by the tentorium cerebelli.
The cerebellum lies posterior to the pons, separated from it through the fourth ventricle
(Aumu¨ller and Wurzinger, 2010). From a superficial point of view, the cerebellum is
divided into horizontal folia. It consists of a left and right hemisphere and a medial
expansion called vermis.
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Figure 3: Overview of the cerebellar layers in a sagittal section. Sagittal section
through the cerebellum showing the different structures of the white and grey matter. The grey
matter consists of three layers, the molecular layer, the Purkinje cell layer, and the granule cell
layer (internal granule layer, IGL). The layers also contain different interneurons. The axons of
granule cells form parallel fibres that are orthogonally to the dendritic arbours of the Purkinje
cells (not shown here) (Butts et al., 2014).
The cerebellum is essential for motor control; and although it does not initiate movement,
it is responsible for coordination. Recent work has shown that the cerebellum additionally
plays a big role in cognitive function, e.g. feed-forward sensory-motor learning, speech,
and spatial memory (Schmahmann and Caplan, 2006; Hatten and Roussel, 2011; Za-
krzewska et al., 2013). Its importance is also highlighted by the fact that the majority of
the mature neurons in the adult brain are in the cerebellum (Butts et al., 2014), most of
them being cerebellar granule neurons (Hatten and Roussel, 2011). The adult cerebellum
exhibits a rather simple histological composition, consisting of the white matter and three
outer layers forming the cortex (Fig. 3). The white matter, containing the cerebellar nuc-
lei, is surrounded by the internal granular layer (IGL), followed by the Purkinje cell layer
(PCL), and the sub-pial molecular layer (ML), comprised of the Purkinje cell dendritic
trees and the axons of the granule cells (Butts et al., 2014).
Input from outside the cerebellum is received by the granule cells which then project to
the Purkinje cells that forward information to the different cerebellar nuclei. Additionally,
a network of interneurons is able to modulate this output (Trepel, 2009).
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1.3.2 Development of the cerebellum
During the early embryonic stages of development, the brain can be divided into three
segments: the prosencephalon (forebrain), the mesencephalon (midbrain), and the rhomb-
encephalon (hindbrain) (Smeyne and Goldowitz, 1989; Mu¨ller and O’Rahilly, 1990). The
cerebellum develops from the rhombencephalon, the most caudal of these segments. This
part of the developing CNS can itself be divided into two sections, the metencephalon and
the myelencephalon. The metencephalon has been shown to build eight swellings (struc-
tural units) on its posterior part, so-called rhombomeres. Rhombomere 1 later forms the
cerebellum (Wingate and Hatten, 1999). This whole posterior section of the developing
metencephalon is called the rhombic lip (RL) (Gilthorpe et al., 2002). The upper rohmbic
lip (URL, rhombomere 1) is responsible for the development of the cerebellum; the lower
part of the RL (LRL, lower rhombic lip) gives rise to cells that later form parts of the
precerebellar system and cochlear nucleus (Landsberg et al., 2005).
Investigations in mice have shown that the cerebellar ’anlage’ is allocated to the boundary
between the hindbrain and the midbrain as early as E8.5 (Butts et al., 2014). Two days
later, around E10.25, the cerebellar nuclei and cerebellar cortex begin to be generated by
a complex pattern of cell movement and neurogenesis (Hatten and Heintz, 1995; Hatten
and Roussel, 2011). The Purkinje cells of the cerebellum and the deep cerebellar nuclear
neurons are thought to arise from the ventricular zone (VZ) which lies in the roof of the
fourth ventricle. During days E11 to E14, Purkinje progenitors migrate from the VZ into
the cerebellar ’anlage’ (Morales and Hatten, 2006). Proliferating cells that later form
the external granular layer (EGL), birthplace of the granule neuron, emigrate from the
rhombic lip around E12.
The EGL can still be found in newborns as the outermost layer of the cerebellum. During
the early post-natal phase, granule cells from the EGL migrate into inner parts of the
cerebellum underneath the Purkinje cell layer to form the internal granular layer (Mu¨ller
and O’Rahilly, 1990). For granule cells to exit the cell cycle and migrate into the IGL,
several processes need to be completed. On postnatal days two to four (P2-4), granule cell
progenitor (GCP) proliferation within the EGL is influenced by various signalling path-
ways. At P5-8, a peak period of proliferation can be observed, hence, precursor cells are
mostly isolated around this age for further studies (Roussel and Hatten, 2011). Starting
from birth up until P14, the progenitor cells exit the cell cycle and can be found in the
inner section of the EGL.
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From there, they migrate into the inner cerebellar parts underneath the Purkinje cell
layer along the radial fibres of the Bergman glia (Edmondson and Hatten, 1987). This
new formed layer is called internal granular layer. Migration is thought to be completed
around P20 (Hatten and Heintz, 1995). Only the IGL - not the EGL - can be found in
the mature brain.
1.4 Medulloblastoma
Medulloblastoma (MB) is the most common malignant tumour of the central nervous
system in children (Kool et al., 2008; Taylor et al., 2012). MBs can also be found in
other age groups, such as infants and adults, however, it accounts for only 1 % of adult
CNS tumours (Giordana et al., 1999). Medulloblastomas are a heterogenous class of
embryonal tumours and are divided into several subgroups depending on their histological
and genetical characteristics (Louis et al., 2016b). These genetical characteristics include
anomalies in pathways that are essential to the development of the hindbrain, e.g. the
WNT and SHH pathway (Roussel and Hatten, 2011). Due to the differences in the MB
subgroups, treatment has shown to be difficult and new strategies try to design subgroup-
specific therapies. Survival of patients with MB is also dependent on the group and reaches
from very good prognosis with over 90 % 5-year survival rates, to very poor prognosis with
about 30 % 5-year survival rates (Northcott et al., 2011). Medulloblastomas are rapidly
growing, but non-invasive. Interestingly, unlike other brain tumours, MBs metastasize
frequently within the CNS, however, extraneural metastases are rarely found (Dufour
et al., 2012).
1.4.1 Medulloblastoma subgroups
The latest version of the ’WHO classification of tumours of the central nervous system’
was published in 2016. Here, for the first time, the WHO defines different classifications
of medulloblastoma: one being histologically defined subgroups; the other genetically
defined ones (Louis et al., 2016a).
For this project, the genetically defined subgroups are of special interest. There are
four distinct genetically defined subgroups to date. The WHO differentiates between
MB with activation of the WNT signalling pathway, MB with activation of the SHH
signalling pathway, with distinguished groups of TP53-mutants and TP53-wildtype, and
non-WNT/non-SHH MBs called groups 3 and 4 (Louis et al., 2016b,a). An overview of
the genetically defined groups and their histological counterparts is given in Fig. 4.
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Taylor et al. (2012) published the first consensus of MB subgroups outlining that ”there
were four principal transcriptional subgroups of medulloblastoma, with many of these sub-
groups showing a subsequent level of hierarchical structure that will be designated the sub-
types of the subgroups”. The first two subgroups were named due to the pathway that is
thought to play an important role in the pathogenesis of the respective group. Following,
a short outline of the different groups and their characteristics is given.
WNT The WNT subgroup is best known for its very good long-term prognosis, with a
5-year survival rate of over 90 % (Ellison et al., 2011). Most of the tumours in this group
have classic histology. Interestingly, although males are usually more likely to develop
medulloblastoma, WNT-activated MB show a 1:1 ratio for male to female patients. The
tumour does normally not occur in infants (Fig. 4) (Taylor et al., 2012).
Figure 4: Overview of medulloblastoma subgroups. Table gives an overview of the
four MB subgroups and their main characteristics, i.e. genetic profile, histology, prognosis, and
demographics. Male to female ratios are shown using the standard sex symbols. Ratios of age
groups are shown in comparison of infant (I) to child (C) to adult (A) patients. Table adapted
from Louis et al. (2016a), original content reprinted with kind permission from Dr. David W.
Ellison, St. Jude Children’s Research Hospital in Memphis, TN US.
SHH The Sonic hedgehog (SHH) signalling pathway is thought to be the cause for
development of MBs in group 2. Germline mutations in PTCH and SUFU as well as
somatic mutations in GLI1, GLI2, PTCH, SMO, and SUFU, all of which belong to the
SHH pathway, have been found in SHH MBs (Taylor et al., 2002; Slade et al., 2011; Taylor
et al., 2012).
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The location of SHH MB is distinct, depending on the age group: in adults, SHH MBs
are located in the cerebellar hemispheres, however, infant SHH MBs are often seen in the
vermis (Wefers et al., 2014). SHH-associated tumours can be found in both infants and
adults with no preference for sex (ratio 1:1). Prognosis for this subgroup can be described
as ’intermediate’ as it is worse than that of the WNT subgroup, but better than the poor
outcome for patients of group 3 (Taylor et al., 2012).
Group 3 Medulloblastomas in group 3 mostly show ’classic’ histological features. To
classify a tumour as a member of group 3, its transcriptional profile has to match others
from the same group (Kool et al., 2008). There is no defined marker for this subgroup,
although a few have been proposed (Northcott et al., 2011; Hatten and Roussel, 2011).
Tumours in group 3 are more often found in males and almost never occur in adults
(Taylor et al., 2012). MBs in this group have a very poor prognosis.
Group 4 MBs in group 4 are described as the ’prototypical medulloblastoma’ (Taylor
et al., 2012). As with group 3, MBs from group 4 are identified through matching tran-
scriptional profiles. An isochromosome 17q is often found in these tumours (Kool et al.,
2012). Similar to group 3, tumours in group 4 show a high male-to-female ratio; prognosis
is comparable to group 2.
For this thesis, focus was on Sonic hedgehog associated medulloblastoma of the adult
brain (group 2), as this group was found to have additional somatic mutations in TCF4
in 14 % of cases (Kool et al., 2014).
1.4.2 SHH signalling pathway
The Sonic hedgehog signalling pathway is essential for human development, especially
for the organisation of the brain. And even after successful development, SHH remains
important; for example, for the cell division of adult stem cells (Choudhry et al., 2014).
Its constitutive activation in the postnatal cerebellum has been shown to be sufficient to
initiate MB development in mice (Schu¨ller et al., 2008; Rimkus et al., 2016). The SHH
pathway is thought to be defective in more than 25 % of medulloblastomas (Gilbertson
and Ellison, 2008). Consequently, the SHH/PTCH (Patched) signalling pathway is the
best studied pathway in MBs (Rosenfeld et al., 2009).
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Sonic hedgehog belongs to a family of three proteins named the Hedgehog family, with
the other two being Desert hedgehog and Indian hedgehog (Echelard et al., 1993; Marigo
et al., 1995). The main responsibility of SHH is the upregulation of transcription of
numerous target genes (Ingham et al., 2011). This protein acts as a morphogen, i.e. its
various concentrations determine the cell’s fate in different ways. Hence, exposure to the
different levels of SHH will result in several distinct cells. Low concentrations of SHH
lead to ventral neurons, high concentrations induce motor neurons, whereas very high
concentrations produce so-called floor plate cells (Ericson et al., 1997; Jessell, 2000).
Figure 5: Sonic hedgehog (SHH) signalling pathway. Left: In absence of SHH,
Patched (PTCH) represses the function of Smoothened (SMO). This causes SUFU to retain the
GLI proteins in the cytosol and GLI is either ubiquitylated and degraded by the proteasome
or cleaved and turned into a transcriptional repressor. Only the transcriptional repressor forms
of GLI are able to enter the nucleus and inhibit transcription. Right: In the presence of
SHH, PTCH cannot repress SMO which translocates into the cell membrane. SMO mediates
downstream signal transduction which leads to the phosphorylation of SUFU and subsequent
dissociation of GLI1 and GLI2 which can now enter the nucleus to activate transcription.
Although interactions within the SHH pathway are complex and not yet fully understood,
the main features can be described as follows (Fig. 5): SHH is able to drive proliferation of
granule cell precursors by binding to the transmembrane receptor Patched (PTCH). In the
absence of SHH, PTCH represses the function of Smoothened (SMO), another transmem-
brane receptor normally located in intracellular vesicles (Choudhry et al., 2014). SMO is
a seven-transmembrane receptor responsible for the activation of the transcription factors
GLI1 and GLI2 and the inhibition of the trancriptional repressor GLI3.
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These transcription factors serve as regulators of the transcriptional programme in the
cell nucleus (Rosenfeld et al., 2009).
As long as SHH is absent, GLI is cleaved and following a series of chemical reactions the
C-terminus is ubiquitylated which leads to its degradation by the proteasome (Ingham
et al., 2011). This process also yields transcriptional repressor forms of GLI, prevent-
ing activation of SHH target genes (Rubin and de Sauvage, 2006). Furthermore, SUFU,
another negative regulator of the SHH pathway interacts with the three uncleaved GLI
proteins in order to retain them in the cytosol (Jia et al., 2009). In the presence of SHH,
PTCH becomes inactive allowing SMO to translocate to the membrane and therefore
become activated. The activation of SMO triggers a cascade of reactions allowing the
phosphorylation of SUFU which thus dislocates from GLI. GLI can now find its way into
the nucleus to initiate transcription (Ingham et al., 2011).
Due to its role in the SHH signalling pathway, SMO has been found to exhibit onco-
genic potential and activating mutations will give rise to neoplasia, i.e. SHH-associated
medulloblastoma (Choudhry et al., 2014). SMO is therefore not only a popular target for
new treatment strategies but also widely used in animal models to mimic SHH-associated
MB (see Section 1.4.5).
1.4.3 Origins of medulloblastoma
Knowing the origins of a tumour, the cells it arises from and their exact location, is a
prerequisite for generating matching animal models and targeted treatment strategies.
As mentioned before, medulloblastoma is a heterogeneous group of tumours that can be
divided into several subgroups due to their genetic background. Consequently, different
cell populations of the rhombic lip give rise to different MB subgroups (Gibson et al.,
2010; Grammel et al., 2012).
Gibson et al. (2010) were the first to demonstrate that the WNT MB subtype origin-
ates from cells of the dorsal brainstem outside of the cerebellum; these cells are precursor
cells of the precerebellar rhombic lip (rhombomere 6-8) that migrate and later form nuc-
lei throughout the developing hindbrain. As for the SHH-associated MB, Grammel et al.
(2012) were able to show that two distinct cell populations give rise to this particular
tumour entity. It was already known that activation of the SHH pathway in cerebellar
granule neuron precursors (CGNP), a progenitor population of the URL (rhombomere 1,
see Section 1.3.2) and in precursors of the EGL is able to give rise to SHH MBs (Schu¨ller
et al., 2008; Behesti and Marino, 2009).
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Grammel et al. (2012) then demonstrated that SHH MBs can also arise from granule
neuron precursors of the cochlear nuclei, a cell population from the auditory lower rhombic
lip (rhombomere 2-5). The cellular origins for groups 3 and 4 have yet to be identified.
Besides the identification of different cell populations giving rise to the different MB
subgroups, investigations on the exact localization of the tumours have been carried out
and shown to be age-dependent as well as dependent on the age of initiation (Wefers
et al., 2014; Ohli et al., 2015). Wefers et al. (2014) were able to show that localisation of
SHH MBs differed between infant SHH MB and adult SHH MB, while Ohli et al. (2015)
could demonstrate that the age of initiation determines the localization of the tumours.
1.4.4 Symptoms, diagnosis, and current treatment strategies of
MB
Symptoms associated with MB are mostly non-specific in the beginning and mainly caused
by increased cranial pressure, leading to headache and vomiting. Patients can further be-
come listless. With time, patients will develop ataxia and more cognitive problems as
well as dizziness. Especially infants can also develop a hydrocephalus (Polkinghorn and
Tarbell, 2007). Symptoms of increased cranial pressure usually start a few months before
diagnosis and worsen with tumour growth. Depending on the metastatic state of the
tumour, other symptoms are possible. Different magnetic resonance (MR) imaging tech-
niques are normally used for diagnosis and in case of MB reveal a mass in the posterior
fossa (Polkinghorn and Tarbell, 2007).
Current treatment strategies for medulloblastomas encompass surgical resection, radi-
ation, and chemotherapy independent of the MB subgroup. Over the past 20 years,
progress has been made regarding treatment for MB patients; currently around 60 % of
patients show a 5-year survival (Rutkowski et al., 2005). Nevertheless, many of the ther-
apies still come with adverse secondary effects and significant morbidity (Gajjar et al.,
2006). Especially the long-term effects of radiation on the immature brains of infants are
of great concern (MacDonald, 2008).
With a better understanding of the disease on a molecular level, new therapeutic ap-
proaches are becoming available, trying to optimise treatment in respect to the specific
subgroup and their characteristics (Roussel and Hatten, 2011). Some of these new drugs
have already been developed and tested in mouse models (Romer and Curran, 2005;
Beauchamp et al., 2011; Lee et al., 2012).
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Further research on the molecular basis of development and progression of medullo-
blastoma will give rise to new therapeutic targets and therefore treatment strategies.
1.4.5 Medulloblastoma mouse models
For a better understanding and the possibility to investigate medulloblastoma in more
detail, mouse models for the different subgroups of MB have been generated. There are
over 20 different mouse models for MB published to date; most of which model SHH MBs
(Wu et al., 2011; Po¨schl et al., 2014; Neumann et al., 2017). Po¨schl et al. (2014) were
able to show that the majority of the known SHH MB mouse models match adult SHH
MB in humans. They further showed that especially medulloblastoma driven by a SMO
mutation, constitutively activating the SHH pathway, match adult SHH MB best. These
mouse models were thus used for this project.
Schu¨ller et al. (2008) published the hGFAP-cre::SmoM2-YFPfl/+ mouse model in which
the Cre recombinase is expressed under the Human glial fibrillary acidic protein (hGFAP)
promoter (Zhuo et al., 2001). In these mice, CRE expression begins on E13.5 in the for-
brain and from then on, SMO will be constantly activated (Zhuo et al., 2001). HGFAP
is mainly expressed in astrocyctes in the adult brain. However, cells that express the Cre
recombinase under the hGFAP promoter were found to be radial glia that generate most
cerebellar cell types, also including (cerebellar) granule neuron precursors, interneurons,
forebrain stem cells, and astrocytes (Spassky et al., 2008; Schu¨ller et al., 2008). Schu¨ller
et al. (2008) further published the Math1-cre::SmoM2-YFPfl/+ mouse model, which also
leads to the development of adult SHH MB (Po¨schl et al., 2014). Expression of Math1
can be detected as early as E12.5 in granule cells of mice; by E17, all granule precursors
express Math1 (Machold and Fishell, 2005). Thus, the Math1-cre system can be used for
specific knockouts in granule precursors.
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The aim of this study was to investigate the importance of TCF4 in the development of
the cerebellum and its influence on growth and progression of Sonic hedgehog associated
medulloblastoma.
A recent study, published in collaboration with Stefan Pfister’s group (German Cancer
Research Center, Heidelberg), found that in a group of 50 adult patients with SHH MB,
14 % (7 adult patients) carried a somatic mutation in TCF4, making it one of the most
frequently mutated genes in SHH MB (Kool et al., 2014). Since the growth of medullo-
blastoma, especially in adults, has not been fully understood and a successful therapy has
yet to be developed, TCF4 is an interesting target to study; not only in terms of its role
in the growth of MB but also for screening of useful therapeutics later on. Interestingly,
mutations in TCF4 have also been identified as the cause of Pitt-Hopkins syndrome. How
the haploinsufficiency of TCF4 causes this disorder, the accompanying brain abnormal-
ities, and intellectual disability however, remains to be understood. Hence, investigating
the influence of TCF4 on cerebellar development will further increase the understanding
of PTHS and its molecular mechanisms. At the start of this project, no PTHS mouse
model was published and this study therefore aimed at testing whether the TCF4 mouse
model, generated for the present study, is suitable to also serve as a model for PTHS.
In the context of this thesis, different sets of experiments were performed to gain more
insight into the function of TCF4. Mouse models to mimic Pitt-Hopkins syndrome as well
as SHH MB carrying a Tcf4 knockout were established with the intention to investigate
prenatal and postnatal knockouts of Tcf4 in vivo. For a better understanding, the mouse
models were analysed using different histological techniques. Granule precursor cells were
used to establish primary cell lines with the aim to understand cell growth and prolif-
eration following a TCF4 loss in vitro. Of further interest was the function of TCF4 in
medulloblastomas with an impaired SHH signalling pathway, which was examined using
a human SHH MB cell line transfected with wild-type (WT) TCF4 and different known
mutant TCF4 proteins that were recently found in MBs.
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3.1 Human data
In a series of 130 patients with medulloblastoma and a secured pathological activation of
the SHH signalling pathway, 14 % of adult patients (7 out of 50 patients >18 years) were
found to have somatic mutations in the TCF4 gene (Kool et al., 2014). This intriguingly
high number of SHH MB patients carrying a somatic TCF4 mutation was the reason to
investigate the influence of TCF4 on growth and progression of medulloblastoma.
3.1.1 TCF4 expression levels in medulloblastoma
To gain more insight into the importance of TCF4 in growth of medulloblastoma, mRNA
expression profiles of medulloblastomas were screened. Therefore, a sample of 464 medullo-
blastoma expression profiles, available through the open access database R2 (R2: microar-
ray analysis and visualization platform, http://r2.amc.nl), with 122 being SHH-associated
medulloblastoma, were analysed. The 464 available patient data sets consisted of several
sets produced by different research groups and had to be normalised to allow for direct
comparison (see Section 7.2.5).
The mRNA expression of TCF4 in medulloblastoma was compared to mRNA expression
of TCF4 in healthy brain tissue, in specific, foetal cerebellum and adult cerebellum to
examine whether the base line level of TCF4 was altered. The results showed that the
mRNA levels of the whole SHH MB subgroup (112 patients) are significantly higher in
comparison to the levels found in foetal and adult cerebellum respectively (p=0.0002 and
p<0.0001). Although the expression levels of the SHH subgroup are relatively scattered
(Fig. 6A), the mean expression level is clearly raised compared to the normal tissue and
lies more than one standard deviation (SD) above the base line. Apart from the elev-
ated mRNA levels in medulloblastoma, it was identified that during development of the
brain, i.e. foetal cerebellum, TCF4 levels are significantly higher compared to the adult
cerebellum (p=0.0068). This is in accordance with the knowledge that TCF4 regulates
neurogenesis (Sepp et al., 2011).
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Figure 6: TCF4 mRNA expression in MB is significantly increased.
(A) TCF4 mRNA expression in the cerebellum (foetal and adult) and SHH MB. Results showed
significantly higher levels for SHH MB. (B) TCF4 expression in distinct molecular subgroups
of MB. SHH MB TCF4 mRNA expression levels were significantly higher compared to all other
groups. Red dots indicate cases with known somatic TCF4 mutations. Relative gene expression
values were calculated using z-scores. Scale on y-axis indicate the number of standard deviations
by which the value of the expression level is different from the overall mean. Bars indicate the
mean of each group. Groups were compared using two-tailed t-tests and Mann-Whitney-U tests
respectively. ** = p< 0.01, **** = p< 0.0001.
Moreover, mRNA expression levels of TCF4 were compared between the different MB sub-
groups to examine if the elevation of TCF4 expression is unique to subgroup 2. Fig. 6B
illustrates that mRNA expression was significantly elevated in the SHH subgroup com-
pared to all other analysed groups (p<0.0001). In addition to the SHH subgroup, also
the WNT subgroup showed elevated expression levels, whereas group 3 and 4 showed a
mean TCF4 expression level below the overall mean. A comparison between the different
age groups within the SHH subgroup (infant MB, childhood MB, adult MB) resulted in
no significant difference in TCF4 expression (Fig. 27, Appendix).
These results highlight that the TCF4 expression in SHH-associated medulloblastoma
is highly elevated not only compared to healthy tissue but also compared to the other
subgroups. This raises the question whether elevated TCF4 levels influence the patient’s
outcome, i.e. the overall survival.
3.1.2 Analysis of long-term survival of MB patients
The data sets available on R2 did not only contain the mRNA expression levels of the 464
patients but also the survival data for the majority of patients. It was therefore possible
to link the expression levels of TCF4 with the overall survival.
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Interestingly, the generated Kaplan-Meier plots in Fig. 7 demonstrate that a high level of
TCF4 is correlated with a better overall survival. A high level of TCF4 was defined as
a z-score of 1.5 and above.3 Comparing all SHH MBs, the results revealed a significantly
better survival for patients with high TCF4 levels (p=0.045). A 5-year survival rate of
over 90 % for patients with high TCF4 levels was calculated compared to 70 % for low
TCF4 mRNA levels.
Figure 7: Kaplan-Meier plots for SHH MB reveal overall better survival for
patients with high TCF4 levels. (A) Kaplan-Meier analysis reveals a significantly better
survival for SHH MB patients with high expression of TCF4. (B) A similar result was observed
regarding only adult patients with SHH MBs. Analysis was performed using a logrank test. A
high mRNA level was defined as a z-score of 1.5 and above. Bars mark events of death.
These results suggest that the expression of TCF4 is advantageous for patients with
SHH-associated medulloblastoma, strengthening the hypothesis that TCF4 functions as
a tumour suppressor (Herbst et al., 2009a). However, the data available do not allow to
draw a definite conclusion as only mRNA expression was measured and a direct correl-
ation between RNA and protein levels cannot be assumed (Vogel et al., 2010). This is
highlighted by the fact that the two patients with known TCF4 mutations (shown as red
dots in Fig. 6) are expressing TCF4 mRNA at different levels although their mutations -
R157X and R174X - are both nonsense mutations and no functioning protein is produced
(Fig. 9, Section 3.2.2).
3The z-score defines how many standard deviations a data point is below or above the (population)
mean, and is often used when several different data sets are combined to one. I.e. a deviation of 1.5 SD
from the mean was defined as high level of TCF4 expression.
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Evaluating the data from patients with adult SHH MBs only, it is evident that adult
patients with a high expression level of TCF4 have a better overall survival (Fig. 7B),
though not with a significant difference (p = 0.088). It should be noted however, that
there were only eight patients in the ’high TCF4 level’ group and a larger cohort might
show a more significant result.
3.2 Investigation of known TCF4 mutations
3.2.1 TCF4 mutations in MB
A series of 133 SHH MBs was previously sequenced in collaboration with the German
Cancer Research Center (Kool et al., 2014), with 50 patients being 3 years and younger
(infant SHH MB), 33 patients aged 4-17 years (childhood SHH MB), and 50 cases being
over 18 years (adult SHH MB). Somatic mutations in the TCF4 gene were found in eight
cases (Fig. 2), which accounts for a total of 6 % of patients. However, seven of these
patients were adults, i.e. over 18 years old, and the eighth patient was already 17 years of
age at diagnosis, so that 14 % of patients with adult SHH MB exhibited TCF4 mutations
(7 out of 50).
Table 2: Mutations found in TCF4 in SHH MBs. All except one patient, 17 years
of age, were adults. Mutations were found throughout the gene and were of different kind, i.e.
frame-shift (fs), deletion (del), nonsense (X), missense, and splice site. Mutations R157X and
R174X belong to patients shown as red dots in Fig. 6 and the same mutations were also found in
patients with PTHS. The mutations are denoted according to the TCF4-B− protein sequence.
Mutation Age of patient in years
Q619X 17
216 219del 25
D304fs 25
R157X 28
R174X 32
451 453del 38.5
V613F 46
splice site 46
No cluster of somatic mutations was found in TCF4. Instead, the mutations were scattered
throughout the gene, affecting different domains of the protein (Fig. 8). Furthermore, the
different kinds of mutations were rather versatile.
24
3.2 Investigation of known TCF4 mutations
Deletions, frame shift mutations, nonsense mutations as well as missense mutations and
one splice site mutation were identified. Two of the mutations found during sequen-
cing - R157X and R174X - have been described before as germline mutations in patients
with Pitt-Hopkins syndrome (Sepp et al., 2012). To determine the functionality of these
mutants and investigate their influence on growth and progression of medulloblastoma,
five of the above listed mutations were designed using site directed mutagenesis and trans-
fected into the MB cell line DAOY.
Figure 8: Structure of TCF4 protein sequence highlighting known TCF4 muta-
tions. Positions of TCF4 mutations identified in SHH MB shown on a scheme of TCF4-B−.
Note that except Q619X, which was found in an 17-year-old patient, all mutations were detec-
ted in adult SHH MB patients (>18 years). Asterisks mark mutations that had previously been
identified in the germline of patients with Pitt-Hopkins syndrome. Different domains are shown
in different colours. Activation domains AD1 and AD2 (purple and green), nuclear localisation
sequence (NLS, light blue), and the basic helix-loop-helix domain (bHLH, turquoise). Mutations
are given in Table 2.
3.2.2 Influence of WT TCF4 and TCF4 mutants on proliferation
in a MB cell line
Five out of the eight discovered mutations (R157X, R174X, 216 216del, 451 453del, V613F)
as well as WT TCF4 were cloned into the MSCV-IRES-GFP vector and subsequently
transfected into the MB cell line DAOY to study the functionality of the (mutated) pro-
teins and determine their influence on cell growth. The DAOY cell line is an adherent
cell line derived from a desmoplastic cerebellar medulloblastoma from a Caucasian male
at the age of four (Jacobsen et al., 1985), that has been identified to belong to the SHH
subgroup of MB (Liang et al., 2015).
First, the MB cell line was tested for its expression of TCF4 and found not to express the
protein, i.e. cells could not be stained for TCF4 (Fig. 9A, no red fluorescent cells). The
experiment was then carried out in eight different settings. A control with no plasmid
was performed to determine the base line cell proliferation rate. The DAOY cells were
furthermore transfected with the MSCV-IRES-GFP backbone alone to determine if the
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transfection of the plasmid itself influences cell growth, assuming that it does not. DAOY
cells were then transfected with WT TCF4 to study the effect on cell proliferation rates of
introducing TCF4 to a TCF4-deficient MB cell line. Finally, the DAOY cell cultures were
transfected with the TCF4 mutants R157X, R174X, 216 219del, 451 453del, and V613F
to investigate their functionality and influence on cell growth in MB.
The transfected and fixated cells were initially stained for a combination of TCF4, GFP
(green fluorescent protein), and DAPI (4’,6-diamidino-2-phenylindole). Staining of GFP
(green) was used to determine cells that were transfected, and the TCF4 staining (red)
gave information whether a functioning TCF4 protein was produced (Fig. 9A-H, orange
fluorescent cells are positive for GFP and TCF4). However, the TCF4 antibody only
binds to a specific domain (AAs 468-525), and the staining therefore only verifies if this
specific domain is present and functioning (Fig. 32, Appendix). Truncated proteins that
are missing domains other than AA 468-525 will be detected by the antibody. The trans-
fected cells were additionally stained with antibodies against BrdU (Bromodeoxyuridine),
GFP, and DAPI; with GFP (green) again visualizing cells that were transfected and BrdU
(red) marking the cells that were actively proliferating. For the evaluation of proliferation
rates, only double positive cells (orange) were counted (Fig. 9J-Q and R).
Staining of TCF4 showed that besides the WT TCF4, the mutants 216 219del, 451 453del
and V613F were able to express a TCF4 protein, which can be recognised by the anti-
TCF4 antibody. In particular, Fig. 9I (a magnification of 9H) shows that the V613F
mutant precipitates in the cell. This phenomenon of TCF4 mutants forming protein ag-
gregates has been described before, with mutations found in patients with Pitt-Hopkins
syndrome (Forrest et al., 2012; Sepp et al., 2012). Namely, Sepp et al. (2012) proposed
that ”PTHS-associated mutations in the second helix of the bHLH domain and C-terminal
part of TCF4 induce protein destabilization and aggregation”.
The analysis of the proliferation rates clearly showed that the introduction of WT TCF4
into the DAOY cells decreases the proliferation significantly, from around 50 % (49±2 %)
to less than 15 % (14±3 %) (Fig. 9R). As expected, the transfection of DAOY cells with
the sole plasmid backbone did not alter cell growth and all the effects found can be ac-
credited to the respective version of TCF4. The results illustrate that the mutants R157X
and R174X are non-functioning (no staining of TCF4) and the proliferation rates are not
altered compared to the base line proliferation. Due to the early nonsense mutation of
these mutants (Fig. 8), this was to be expected. The mutants 216 219del and 451 453del
resulted in some function, as seen by the staining for TCF4, and also a decreased cell
proliferation. However, the count of BrdU+ cells is still significantly higher than that for
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the WT TCF4. For the V613F mutant, proliferation rates were not altered which shows
that this TCF4 mutant is non-functioning. This comes as no surprise, since the mutation
occurs in the bHLH domain and, as described above, the mutant protein forms aggregates
in the cell.
Figure 9: See the following page for description.
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Figure 9: WT TCF4 is able to decrease proliferation of DAOY cells signific-
antly. (A-H) DAOY cells were stained with antibodies against TCF4 (red), GFP (green), and
DAPI (blue). (A) DAOY cells do not express TCF4. (B–H) Transfection of DAOY cells with
IRES-GFP plasmids containing either no TCF4, TCF4 WT or the TCF4 mutants shown in
Fig. 8. (I) Magnification of (H) where precipitation of TCF4 in the nucleus can be observed.
(J-P) DAOY cells stained with antibodies against BrdU (red), GFP (green), and DAPI (blue).
(K-P) Transfection of DAOY cells with IRES-GFP plasmids containing either no TCF4, TCF4
WT or the TCF4 mutants. (R) Analysis of proliferation of transfected DAOY cells. Plotted
were the fraction of BrdU+ cells from transduced cells (GFP+) and the baseline proliferation rate
respectively. WT TCF4 reduced proliferation significantly in comparison to unaffected DAOY
cells and all tested mutants. Mutants 216del and 451del showed partial functionality and also
reduced proliferation. Analysis was done comparing cell counts using chi-squared tests. Each
transfection was carried out three times (n=3). Error bars show mean+SD. **** = p<0.0001,
** = p<0.01, n.s. = p>0.05.
It can be concluded that WT TCF4 reduces cell proliferation in a SHH MB cell line
indicating that TCF4 functions as a tumour suppressor, which had already been seen in
the previous experiment (Section 3.1.1).
3.3 Establishing the mouse models
There are several known and well-described mouse models for SHH MB and some
proposed mouse models for PTHS (Sections 1.2.5 and 1.4.5). For the experimental part
of this thesis, several SHH MB mouse models and a Tcf4 mouse model were adjusted
to the project’s needs so that a variety of different transgenic mice with conditional and
inducible knockouts were generated.
Starting from the two basic models, in which the Cre recombinase is expressed
under the control of the hGFAP or the Math1 promoter (Zhuo et al., 2001; Matei et al.,
2005; Schu¨ller et al., 2007), the different mouse models for this project were generated.
Therefore, the already described SHH MB mouse models hGFAP-cre::SmoM2-YFPfl/+
and Math1-creERT2::SmoM2-YFPfl/+ were bred with Tcf4fl/fl mice to create an
additional Tcf4 knockout in the tumourous environment and thus having a tool to
investigate the influence of Tcf4 on growth of medulloblastoma. By using the different
conditional and inducible systems, knockouts of Tcf4 could be controlled easily in a
time- and tissue-specific manner.
To investigate the influence of Tcf4 in cerebellar development, a new mouse model was
established, knocking out Tcf4 solely in a subset of neuronal cells.
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Mice expressing the Cre recombinase under the hGFAP and Math1 promoter were
bred with Tcf4fl/fl mice to generate hGFAP-cre::Tcf4fl/fl and Math1-cre::Tcf4fl/fl mice.
The former mice, following a closer observation, exhibited impressive similarities to the
features found in Pitt-Hopkins syndrome and were proposed as a new model to study
the disease, differing from the models already published (Kennedy et al., 2016; Jung
et al., 2018; Thaxton et al., 2018). This model can be distinguished from other known
PTHS models by the fact that it is the only model that is viable following a homozygous
knockout of Tcf4 giving it the advantage to study a full loss of the gene in the CNS.
As the generated mice loose Tcf4 only in a defined subset of cell lines, it fails to mimic
other PTHS features outside the CNS such as the gastrointestinal changes.
3.4 In vitro loss of Tcf4
A cerebellar granule neuron precursor (CGNP) cell culture carrying a homozygous Tcf4
knockout was established to receive a first impression of the effect of Tcf4 on cell growth
and its function in cerebellar development. Proliferation rates of the CGNP cells were
compared to a wild type CGNP culture. Granule cerebellar progenitors are said to be
the origin of SHH medulloblastoma and the experiment was therefore also of interest
in respect to the influence of Tcf4 on progression and development of medulloblastoma
(Gilbertson and Ellison, 2008; Behesti and Marino, 2009).
Primary cell cultures of CGNP cells were established using Tcf4fl/fl mice aged
five to seven days. CGNPs show a peak period of proliferation around P5-8, so this
age was ideal for generating the cell cultures (Roussel and Hatten, 2011). The granule
precursors were isolated and cultured as described in Section 7.2.2.1. Cells were then
transduced with a virus either carrying the plasmid MSCV-IRES-GFP or MSCV-Cre-
IRES-GFP with the latter causing a knockout of Tcf4. This transduction corresponded
to a post natal knockout of Tcf4 around P6-8. The cells were pulsed with BrdU and
subsequently fixed and stained for BrdU and GFP 24 h post transduction. GFP+ and
BrdU+ double positive cells from both experimental settings were counted and the
numbers compared using a chi-squared test. The cultures were prepared a total of five
times (n=5). The results are given in Fig. 10, where the fraction of BrdU+ cells from all
transduced cells is plotted. It was identified that a total loss of Tcf4 in granule neuron
precursors increased cell proliferation significantly (p<0.0001). The findings from this
experiment further strengthen the assumption that Tcf4 functions as a tumour suppressor.
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Figure 10: Knockout of Tcf4 increases proliferation of CGNP cells. (A-D)
Granule precursor cells of Tcf4fl/fl mice, after transduction with Cre-IRES-GFP to knockout
Tcf4. Stained for DAPI (blue), GFP (green), and BrdU (red). (D) is an overlay of pictures
A-C. (E-H) Control group. Granule precursor cells of Tcf4fl/fl mice after transduction with
IRES-GFP. Cells were stained as above. (H) is an overlay of pictures E-G. (I) Analysis of
proliferation of granule precursor cells after knockout of Tcf4. Results showed that proliferation
increases significantly following the loss of Tcf4. Cell counts were compared using a chi-squared
test. Fraction of BrdU+ cells from transduced cells were plotted. Error bars show mean+SD.
**** = p< 0.0001, n=5. Arrows mark the same cells in pictures A-D and E-H.
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A similar, correlating experiment was conducted in vivo by one of the group’s members
(Malte Hellwig). Math1-creERT2Tcf4fl/fl mice were used for this experiment. The mice
were treated with tamoxifen on P5 and pulsed with BrdU on P7, P12 or P15. Mice
were sacrificed two hours after pulsation and the fraction of BrdU+ cells in the EGL was
determined. The experiments revealed that there was a significantly higher proliferation
for mice carrying a homozygous Tcf4 knockout compared to the controls (data not shown).
These in vivo results were thus in accordance with the findings illustrated in Fig. 10 for
the in vitro experiment.
3.5 In vivo loss of Tcf4
To investigate the effect of a loss of Tcf4 on growth in mice, brain development - with the
main focus on cerebellar development -, and formation of granular layers, several in vivo
experiments were conducted. For a more comprehensive understanding of the function of
Tcf4, knockouts using different promoters - hGFAP and Math1 - were compared and the
knockouts were induced prenatally as well as postnatally (see Section 7.2.3.1).
First, macro-anatomical features were compared. Namely, mouse whole body and brain
weights, including cerebrum and cerebellum weights in specific, were determined. Mouse
brains were then investigated closer, regarding the general organisation of the brain, with
focus on the cerebellum. Further observations were carried out focussing on the formation
of the granular layers, migration of granule cells as well as proliferation and apoptosis
rates.
3.5.1 Macro-anatomical aspects
Mice carrying homozygous Tcf4 knockouts were generally lighter in weight and smaller in
size than wild type mice and mice with heterozygous knockouts (Fig. 11). Observations of
anatomical structures under the microscope (Fig. 14 and 16), as well as macro-anatomical
examinations of mouse brains (Fig. 12), suggested a significant difference in brain sizes
between the examined genotypes. To quantify this effect, whole mice and their brains
were systematically weighed. HGFAP-cre::Tcf4+/+, hGFAP-cre::Tcf4fl/+, and hGFAP-
cre::Tcf4fl/fl were weighed every second day starting from birth. Brain weights as well
as cerebrum and cerebellum weights were measured on day 7, 14, and 21 post partum.
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Figure 11: Loss of Tcf4 in vivo causes growth retardation in mice. Shown are
a hGFAP-cre::Tcf4fl/fl mouse on the left and a hGFAP-cre::Tcf4fl/+ mouse on the right. A
homozygous Tcf4 knockout leads to a thinner and shorter body in comparison the heterozygous
littermate. The left mouse measures 8.2 cm in length (excluding tail) and weighs 16.65 g. The
right mouse is 9.2 cm long and weighs 28.30 g. Mice were siblings and at time of death 60 days
old.
The measurements were visualized by plotting the weight of the investigated body part
against the time of measurement (Fig. 13). Growth curves were not calculated since not
all of the necessary variables could be determined with the data available. Instead, the
parameter ’weight’ was compared using t-tests for the different time points separately. For
whole body weights, t-tests were only carried out for day P21. For all other measurements,
t-tests were carried out for days 7, 14, and 21 post partum (see Tab. 10, Appendix).
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Figure 12: Tcf4 knockout in mice leads to microcephaly. Mouse brains of hGFAP-
cre::Tcf4+/+, hGFAP-cre::Tcf4fl/+, and hGFAP-cre::Tcf4fl/fl are shown at age P3 and adult
stage. Mice with homogzygous knockouts of Tcf4 show marginal differences at P3, however,
are different in length and width at adult stage. Arrows mark view of superior and inferior
colliculus. Depending on the genotype, the colliculus can be partially or almost fully seen.
The results demonstrate that mice carrying homozygous Tcf4 knockouts were lighter on
P21 compared to their wild type littermates as were their brains (p-values for whole body
weight = 0.0656).4 The separate analysis of cerebrum and cerebellar weights demon-
strated that both parts were affected by the Tcf4 knockout. Especially the cerebrum
showed a significantly lower weight on all days tested, i.e. P7, 14, and 21 (Fig. 13, see
also Table 10 in the Appendix). Interestingly, not only did the homozygous knockout
mice show a lower brain weight but also the brains of the heterozygous knockouts were
significantly lighter on P21, hinting at the fact that a heterozygous knockout alone can
cause a microcephaly as seen in Pitt-Hopkins syndrome.
Even more astonishing is the comparison of brain weights of days P14 and P21 in
cerebrum and cerebellum of homozygous KO mice, where a decrease in weight was ob-
served (Fig. 13B). It was later confirmed, that this weight loss is due to a decrease in
proliferation and an increase in apoptosis (see Section 3.5.2).
4For whole body weights, a one-tailed t-test would be justified regarding the fact that patients with
PTHS are known to be smaller and exhibit growth retardation. In case of a one-tailed t-test, p = 0.0328
and is therefore significant.
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Figure 13: Loss of Tcf4 causes a decrease in whole body and brain weights.
(A) Mice with the genotypes hGFAP-cre::Tcf4+/+, hGFAP-cre::Tcf4fl/+, and hGFAP-
cre::Tcf4fl/fl were weighed every second day starting at birth. (B-D) Brain, cerebrum, and
cerebellum weights were determined on P7, 14, and 21. At least three mice were measured for
any given point in time. Results showed that whole brain, cerebrum, and cerebellum weights
are significantly lower for mice carrying a homozygous Tcf4 knockout. The entire weight in
grams for whole body weights and milligrams for brain, cerebrum, and cerebellum weights were
plotted against time in days. Groups were compared using t-tests for P21 only. Error bars show
mean ± SD. **** = p<0.0001, ** = p< 0.01, * = p< 0.05, n.s. = p> 0.05.
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3.5.2 Micro-anatomical aspects
3.5.2.1 Cerebrum
In addition to the macro-anatomical aspects of a prenatal Tcf4 knockout, a micro-
anatomical investigation of the mouse brains was performed. H&E stainings of the
brains of mice aged 7, 14, and 21 days were observed under the microscope. The general
anatomical structure and formation of specific brain parts, such as the hippocampus
and the cerebellar layers, were compared. These are the regions where granule cells can
predominantly be found (Shepherd, 2004), and were therefore of special interest for this
project.
Figure 14: Hippocampus of adult mice is altered due to Tcf4 knockout. H&E
stain of coronal sections through the hippocampus of mice aged 21 days. Formation of hip-
pocampus of mice carrying a Tcf4 knockout was observed to be altered and cells forming the
hippocampus appeared more scattered (bottom right).
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Firstly, the cerebrum of hGFAP-cre::Tcf4+/+ and hGFAP-cre::Tcf4fl/fl mice was com-
pared using H&E stainings from different sections. It was found that the formation of the
hippocampus was altered in mice carrying a homozygous Tcf4 knockout. For illustration,
a coronal section of mice aged 21 days is shown in Fig. 14. It can be seen that the loss
of Tcf4 led to a less differentiated structure of the hippocampus; the formation itself is
altered with important parts missing and the overall number of cells forming the hippo-
campus seems to be decreased. Furthermore, a closer observation of the hippocampus
revealed that the cells are more scattered in mice carrying the knockout compared to wild
type mice. The weight measurements of the cerebrum performed in this project already
indicated that the structure of the brain and or the total cell number must be altered for
the cerebrum to weigh significantly less. In accordance with these findings, Jung et al.
(2018) described that the arrangement of TCF4-expressing cells in the hippocampus of
the Tcf4LacZ mouse was less organised.
Further investigation on the formation of the hippocampus and migration of granule cells
as well as their quantification following a Tcf4 knockout was carried out by one of the
group members leading to a separate project and was therefore not pursued for this work.
3.5.2.2 Cerebellum
One of the main aims of this project was the investigation of the formation of cerebellar
structures following the loss of Tcf4. Therefore, several experiments were conducted to
not only observe cell formation but also measure proliferation and apoptosis rates and
track the migration of granule cells.
TCF4 expression in the cerebellum To investigate the consequences of a Tcf4
knockout in mice, the expression of TCF4 in the cerebellum was analysed. Stainings
for TCF4 in the cerebella of mice aged one week and 2.5 months were prepared as well
as in a SHH-associated MB from a two months old Math1-creERT2::Smofl/+ mouse that
had received tamoxifen on P5. None of the mice were carrying a Tcf4 mutation. As
pictured in Fig. 15, TCF4 is highly expressed in the granule cells of the cerebellum,
shown by the staining of the EGL at P7 and the IGL in the adult mouse. TCF4 was
also highly expressed in tumour tissue as highlighted in Fig. 15C and F. These findings
stand in contrast with the expression analysis published by Jung et al. (2018), who found
the most prominent TCF4 expression in the Purkinje cell layer, which did not show any
TCF4 expression in this study (Fig. 15).
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Figure 15: TCF4 expression in the cerebellum of mice at different ages. Staining
for TCF4 in a (A) WT mouse at P7, (B) adult mouse aged 2.5 months, and (C) a Math1-
creERT2::Smofl/+ mouse aged 2 months which had received tamoxifen on P5. Asterisk marks
the SHH MB, tumour and healthy tissue are separated by a dotted line. (D-F) show a higher
magnification of (A-C). Stainings show that TCF4 is highly expressed in granule cells. EGL =
external granular layer, ML = molecular layer, IGL = internal granular layer.
Anatomical structure H&E stainings of cerebella of mice aged 7 and 21 days with
the genotypes hGFAP-cre::Tcf4+/+, hGFAP-cre::Tcf4fl/+, and hGFAP-cre::Tcf4fl/fl were
observed under the microscope. Fig. 16 visualises clearly that at the age of 7 days,
cerebellar structure and formation in the three different groups were approximately the
same, with all of them showing a distinct EGL, ML, and forming IGL. However, the
cerebellum of the hGFAP-cre::Tcf4fl/fl mice already seemed to be smaller and the cortex
- seen in the magnification - seemed to be thinner. This impression was confirmed by
the comparison of cerebellar weights between WT and homozygous knockout mice for P7
which showed a significantly lower weight (p=0.0023). Two scenarios for the decreased
size had to be considered: (1) either proliferation rates following a Tcf4 knockout were
lower, or (2) apoptosis rates were increased. To distinguish between these two scenarios,
further experiments were conducted, with special attention paid to the migration of the
granule cells.
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Figure 16: Anatomical structure of the cerebellum is distinctly altered due to
loss of Tcf4. H&E stains of mouse brains of mice with genotypes hGFAP-cre::Tcf4+/+,
hGFAP-cre::Tcf4fl/+ and hGFAP-cre::Tcf4fl/fl at P7 (A-C) and P21 (D-F). Lobules are
marked and named in (A) and (D). Magnifications show cortex of cerebellum of lobulus V.
(G-H) magnification of lobules IX and X stained for PAX6. On P7, mice with a homozygous
Tcf4 knockout exhibit a slightly smaller cerebrum and thinner cortex. More extinct effects
can be seen on P21 where the cerebellum is exceedingly smaller. The formation of lobules IX
and X is clearly altered and granule cells are scattered. EGL = external granular layer, ML =
molecular layer, IGL = internal granular layer.
Regarding the histology of the cerebella, distinct alterations in the structure of the cere-
bellum in mice carrying a homozygous loss of Tcf4 was observed for mice at P21. Not
only was the cerebellum smaller in size, which was confirmed in measuring cerebellar
weights (Fig. 13) but also the formation of granule cells, especially in lobules IX and X,
was different from that seen in wild type mice (Fig. 16D-F and G-I).
For a better investigation of lobules IX and X, brains were stained using Paired box protein
6 (PAX6), a marker for granule cells (Chung et al., 2010). Staining of PAX6 highlights
clearly that granular cells in lobules IX and especially X in mice carrying a homozygous
Tcf4 knockout were scattered heavily and the formation of the internal granular layer
was altered. It seemed that migration of granule cells failed and the cells ’got stuck’ in
the molecular layer.
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Experiments carried out using the hGFAP promoter were later repeated using the Math1
promoter with very similar results. The size of the cerebellum of mice with a homozygous
loss of Tcf4 was smaller compared to WT mice (Fig. 29, Appendix). However, the effects
seen here were not as distinct as seen with the hGFAP promoter which might be due to
the fact that more cell lines are affected in hGFAP-cre mice (Machold and Fishell, 2005;
Spassky et al., 2008).
Proliferation and apoptosis rates To unravel the cause of the observed micro-
cephaly, the proliferation rate in the EGL of mice aged 7 days was determined. Mice were
pulsed with BrdU 2 h before decapitation and sagittal sections were prepared. Embedded
tissues were then stained for BrdU; the BrdU+ fraction in the EGL was calculated
and values were compared. Proliferation rates in lobules IV/V and lobules IX/X were
significantly reduced in homozygous knockout mice compared to the wild-type (Fig. 17G).
Apopotosis rates were compared by staining the embedded tissues for Caspase-3
(CASP3). Caspase-3 is a protein that plays an essential role in cell apoptosis (Harrington
et al., 2008). For mice aged 7 days, the fraction of CASP3+ cells in the EGL in lobules
V and X was determined. There were no significant differences in the apoptosis rates
(Fig. 17H). However, for mice at P14, a significantly increased number of CASP3+ cells
in mice carrying a homozygous knockout in lobules IV/V was calculated (p<0.001,
Fig. 30, Appendix). Apoptosis rates on day 21 were determined for lobules IV/V and
lobules IX/X and total numbers of CASP3+ cells per section were counted. Interestingly,
although significantly higher on P14, apoptosis rates were non-significant in lobules IV/V
on P21. Nevertheless, a tendency of increased apoptosis following a Tcf4 knockout was
observed at P21. For lobules IX/X, a significant higher number of CASP3+ cells in the
mutant mice was determined (Fig. 17I).
This suggests that the difference in brain size due to a homozygous loss of Tcf4 is caused
by a decrease in proliferation and an increase in apoptosis in granule cells. These findings
would also explain the decrease in brain weights from P14 to P21 seen in Fig. 13, as
increased apoptosis starts around two weeks post partum.
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Figure 17: Tcf4 knockout influences proliferation and apoptosis rates of gran-
ule cells significantly. (A-B) BrdU staining of the EGL at P7 in lobulus V. Compared
were the proliferation rates of mice at P7 using the fraction of BrdU+ cells in the EGL. (C-D)
Caspase-3 staining of the EGL at P7 in lobulus V. Fractions of CASP3+ cells in the EGL were
used to compare apoptosis in mice. (E-F) CASP3+ staining of lobulus V in (E) and lobulus X
in (F). Cell counts of CASP3+ cells were determined by section at P21. Arrows mark CASP3+
cells. (G-H) Results show that a knockout of Tcf4 causes a significant difference in prolifer-
ation rates at P7. No significant difference could be determined for CASP3+ counts. (I) For
mice at P21, a significant difference in apoptosis rate was found, when comparing lobules IX/X.
Analysis was done using chi-squared tests (G-H) and t-tests (I) respectively. Error bars show
mean + SD. n.s. = p>0.05, * = p<0.05, **** = p<0.0001.
Migration of granule cells To elucidate the structural alterations seen in mice
carrying a homozygous Tcf4 knockout, the migration of granule cells from the external
granular layer into the internal layer throughout early postnatal development was
inspected more closely. Two different experiments were performed.
Firstly, to receive an estimate on the migratory deficits, the number of granule
cells - made visible through staining of PAX6 - in the molecular layer of lobulus IV/V on
P21 was determined. The migration of granule cells should usually be completed by P20
and thus the number of granule cells in the ML very low (Edmondson and Hatten, 1987).
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The results revealed that there was a significant higher number of PAX6+ cells per
mm2 in the ML of hGFAP-cre::Tcf4fl/fl mice on P21 compared to hGFAP-cre WT mice
(Fig. 18G), suggesting that either migration is slowed down or not completed.
A second experiment was performed aiming to confirm that the granule cells from
the EGL do not migrate properly into the IGL. For this experiment, mice were pulsed
with BrdU on P7 and either decapitated two hours later that same day or sacrificed
seven days after the initial BrdU pulse on P14. The number of BrdU+ cells per mm
in the EGL for day 7 and 14 were counted as well as the BrdU+ cells in the ML.
This was to show that the granule cells, resting in the EGL on day 7, where they
actively proliferate, as suggested by the uptake of BrdU, later migrate into the IGL. Since
BrdU stays in the DNA of the cell for several days, it can still be made visible a week later.
The number of BrdU+ cells on P7 in the EGL and ML were not significant differ-
ent between the two genotypes (Fig. 18L). This result was unexpected, as Fig. 17
showed a significant decrease in proliferation on P7 for the homozygous knockout mice
in the EGL. However, a decreased absolute number of BrdU+ was calculated for the
homozygous knockouts (Mean ± SD = 285.7 ± 44.1) and WT mice (Mean ± SD =
383.9 ± 83.6), yet not significant. The differences in the statistical outcome might also
be explained by the different use of absolute and relative cells counts.
Cell counts of BrdU+ cells on day 7 were furthermore higher in the EGL compared to the
ML which was to be expected since granule cells exhibit mitotic activity with a peak at
P5-8 and start migration 24-48 h later (Roussel and Hatten, 2011; Komuro et al., 2013).
On day 14, the number of BrdU+ cells in the EGL was decreased as cells had migrated
to the IGL; migration is thought to be completed around P20 (Galas et al., 2017). Cell
counts comparing the BrdU+ cells between the two genotypes showed no significant
difference for the EGL (Fig. 18M). However, looking at the numbers for BrdU+ in the
ML, there was a highly significant difference between mice carrying a homozygous Tcf4
knockout compared to wild type mice (Fig. 18M).
These two experiments confirm that a loss of Tcf4 changes the migrating beha-
viour of granule cells, causing them to leave the EGL but not to migrate properly into
the IGL and therefore stay in the ML. This explains the alterations observed in the
formation of the IGL and the rather scattered look of lobules IX and X in the homozygous
knockouts respectively.
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Figure 18: Loss of Tcf4 causes migratory deficits in granule cells. (A-F) Granule
cells are shown in the ML on day P21 in lobulus V. (C+F) Staining for PAX6, arrows mark
granule cells (PAX6+ cells) in the ML. (G) Analysis of number of PAX6+ cells in the ML/mm2
for hGFAP-cre::Tcf4fl/fl mice compared to hGFAP-cre WT mice on P21. There was a significant
higher number of cells in the ML in mice with a homozygous Tcf4 knockout. (H-K) Mice pulsed
with BrdU on P7 and killed of either on P7 or P14. Staining for BrdU shows proliferating granule
cells and their migration on P7 and P14. (L+M) Analysis of number of BrdU+ cells per mm on
P7 and P14 in the EGL and ML. There was no significant difference on P7; for P14 a, significant
difference in BrdU+ cells in the ML of hGFAP-cre::Tcf4fl/fl mice was found. EGL = external
granular layer, ML = molecular layer. Analysis was done using t-tests. Error bars show mean
+ SD. n.s. = p>0.05, ** = p<0.01.
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3.5.3 Mouse model and Pitt-Hopkins syndrome
Haploinsufficiency of TCF4 causes Pitt-Hopkins Syndrome (Amiel et al., 2007). Children
with this form of developmental disorder show distinct features in the structure of their
brains, features that can also be found in the herein described mouse models.
To compare the hGFAP-cre::Tcf4fl/fl mouse model with PTHS, magnetic reson-
ance brain images (MRI) of a 19-months old patient with Pitt-Hopkins syndrome and
from an aged-matched control were analysed.5
Fig. 19 shows a widening of the outer and inner cerebrospinal fluid (CSF) spaces, a
reduced volume of the parenchyma of the subtentorial brain (see also Fig. 31, Appendix)
as well as hypoplasia of the cerebellar hemispheres and vermis in the PTHS patient.
Furthermore, a slight disorganisation of the cerebellar folia is present. There are also
increased signal intensities in the deep cerebellar hemispheres (adjacent to the 4th
ventricle) and the posterior pons. Compared to an age-matched control, the entire corpus
callosum is profoundly thinner. The cisterna magna is widened and a slight increase of
the caudal opening of the 4th ventricle can be seen (Fig. 19).
Very similar MRI findings in PTHS were reported by Amiel et al. (2007). The
authors described a thin corpus callosum with moderate hypoplasia, a marked white
matter hyperintensity in the temporal poles, and small hippocampi in PTHS. Fur-
thermore, Peippo and Ignatius (2011) mention 67 reports from MRI scans of PTHS
patients, of which 64 % were abnormal (43 out of 67). ”Most common abnormal findings
reported are hypoplastic/thin corpus callosum, often more pronounced in the rostral parts,
and enlarged ventricles. Bulging caudate nuclei have been described in 4 individuals
[...]. Additional findings reported include small hippocampi, frontal lobe hypoplasia, thin
hindbrain, and delayed myelination.”(Peippo and Ignatius, 2011).
Several of these features were also observed in the mouse models presented in the
this work, especially the hGFAP-cre::Tcf4fl/fl mice. The reduced volume of the cerebel-
lar hemispheres and vermis can be seen in the mouse model and have been addressed
above (Fig. 12 and Fig. 13). Furthermore, the described disorganisation of the cerebellar
folia can be compared to the structural changes identified in the lobules of mice carrying
a homozygous Tcf4 knockout (Fig. 16). Finally, alterations in the hippocampi have been
described in Fig. 14.
5The images and the radiology report were kindly provided by Prof. Dr. Ertl-Wagner, LMU Munich.
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Figure 19: MRI brain of a patient with PTHS and aged-matched control. MR
images of a 19-months old patient with Pitt-Hopkins syndrome (left) and aged matched control
(right). Top: Transverse plane of the cerebellum (T2). Bottom: sagittal plane of the head
(T2). Images for the PTHS patient show hypoplasia of the cerebellum, the corpus callosum is
profoundly thinner, and the outer and inner CSF spaces are widened. Pictures were received
with kind permission from Prof. Dr. Ertl-Wagner (LMU Munich).
Overall, the mouse model established in this work features many of the key characteristics
that have been described in children suffering from Pitt-Hopkins syndrome. Although the
learning difficulties that go along with this neurodevelopmental disorder have not yet
been investigated in the hGFAP-cre::Tcf4fl/fl mouse model, alterations and structural
differences in the hippocampus of these mice suggest that learning difficulties might be
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present and further research in this direction needs to be conducted. Moreover, patients
with Pitt-Hopkins syndrome also exhibit motor deficits which have been observed in some
of the hGFAP-cre::Tcf4fl/fl mice (video footage available). These mice showed an atactic
style of walking, seemed to be rather insecure when moving, and were even smaller than
their littermates, weighing only around 3 to 5 g at adult stage. Due to the limitations of
this project, it was not possible to follow up on these rather ’special’ mice.
3.6 In vivo loss of Tcf4 in SHH MB
Since Tcf4 was found to be mutated in 14 % of adult SHH-associated MB (Kool et al.,
2014), it was of great interest to investigate a loss of Tcf4 in a medulloblastoma mouse
model. Two different mouse models were used for this part of the project. First, loss
of Tcf4 in SHH MBs was examined using hGFAP-cre::Tcf4fl/flSmoM2-YFPfl/+ mice in
comparison to hGFAP-cre::Tcf4+/+SmoM2-YFPfl/+ mice, creating a prenatal knockout
of Tcf4 and a constitutively active SMO. Survival rates of the different genotypes were
determined as well as proliferation and apoptosis rates. Second, the inducible system
Math1-creERT2 was used to create a postnatal knockout of Tcf4 on day five, together
with an activation of the SHH signalling pathway by introducing a Smo mutation. Again,
survival rates were measured.
3.6.1 Prenatal loss of Tcf4
To improve the understanding of the impact of Tcf4 in the development and progression of
medulloblastoma, the hGFAP-cre::Tcf4fl/flSmoM2-YFPfl/+ mouse line was established.
Survival rates of mice carrying a Smo mutation and a Tcf4 mutation simultaneously were
compared to those mice solely carrying a Smo mutation to determine whether a prenatal
loss of Tcf4 influences the survival of mice. Mice were examined on a day-to-day basis
by the staff of the animal facility and notice was given as soon as mice showed symptoms
(e.g. hyperplasia of the skull, refusal to eat, general illness). The mice were sacrificed
as soon as they were in a bad physical stage. Analysis of survival rates was carried out
using a Kaplan-Meier plot and tested for significance using a logrank test. As Fig. 20
illustrates, no difference in survival was found, suggesting that an additional loss of Tcf4
in SHH MB does not affect the overall survival. All mice died between the ages of 13 and
21 days.
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Figure 20: Prenatal loss of Tcf4 does not alter survival rates in SHH MB.
Kaplan-Meier plot for SHH MB with prenatal knockout of Tcf4. Survival rates for the three
different genotypes observed showed now significant difference. Mice died between two and three
weeks of age. Statistical analysis was carried out using a logrank test.
Cell proliferation and apoptosis rates were determined in the same fashion as described
before (see Section 3.5.2.2, p. 36ff). Embedded tissues were stained for CASP3 to measure
apoptosis and the mitosis-specific marker phospho-histone H3 (PHH3) for determination
of proliferation. Due to the anatomical structure of the medulloblastomas, the cerebellar
layers were non-existent and observation was done throughout the tumour tissue.
The investigation of cell proliferation did not show any significant difference for the two
time points observed, i.e. P13 and P17 (Fig. 21). This stands in contrast to the results
determined with a sole homozygous Tcf4 knockout as pictured in Fig. 17, where the
loss of Tcf4 in hGFAP-cre::Tcf4fl/fl mice led to a decrease in proliferation. As for the
apoptosis rates on P17, but not on P13, the number of CASP3+ cells was significantly
higher in the population carrying a homozygous Tcf4 mutation. This was observed
likewise in mice not carrying a Smo mutation (Fig. 17).
These findings indicate that a prenatal loss of Tcf4 has a strong effect on apop-
tosis, independently of the constitutive activation of the SHH signalling pathway, and
therefore the development of MB. The prenatal loss of Tcf4 does not interfere with the
overall survival of the mice and does not alter cell growth. These results, however, are
in contrast to the hypothesis that Tcf4 functions as a tumour suppressor (Herbst et al.,
2009b), providing evidence that the function of Tcf4 might be time-sensitive, i.e. there
are differences in a prenatal versus a postnatal knockout.
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Figure 21: Prenatal knockout of Tcf4 in SHH MB increases apoptosis rates
but does not influence proliferation. (A-D) H&E stains of cerebella with SHH MB in
mice with WT and homozygous knockout of Tcf4 and activation of SMO. Additional stainings
for PHH3 and CASP3 are shown. (E-H) Statistical analysis of fraction of PHH3+ and CASP3+
cells for P13 and P17. No significant difference in PHH3+ cells at P13 and P17 was found. No
increase in apoptosis was determined for P13, however, on P17 a homozygous knockout of Tcf4
caused a significant increase in CASP3+ cells. Total numbers of stained cells were compared
using a chi-squared test. Error bars show mean+SD. n.s. = p>0.05, * = p<0.05. Genotypes
in the statistical analysis are simplified to Tcf4+/+ (hGFAP-cre::Tcf4+/+SmoM2-YFPfl/+) and
Tcf4fl/fl (hGFAP-cre::Tcf4fl/flSmoM2-YFPfl/+) for better illustration.
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3.6.2 Postnatal loss of Tcf4
Besides looking into a prenatal knockout of Tcf4 in respect to the development of medullo-
blastoma, a postnatal knockout of Tcf4 with a constitutive activation of the SHH sig-
nalling pathway was also examined.
Figure 22: Postnatal Tcf4 knockout does not alter survival in SHH MB.
Survival rates of mice of different genotypes expressing the Cre recombinase under the Math1
promoter, using the inducible Math1-creERT2 system, were plotted in a Kaplan-Meier plot. The
Tcf4 knockout and activation of the SHH signalling were induced on day 5 through a tamoxifen
injection. No significant differences were found when comparing the different genotypes with
Tcf4 and Smo mutations. Analysis was carried out using a logrank test.
Therefore, the survival rates of mice of different genotypes using the inducible Math1-
creERT2 system were determined (Fig. 22). These mice express the Cre recombinase
under the Math1 promoter and a Tcf4 loss and activation of SMO were induced
through tamoxifen injection on P5. Mice carrying sole Tcf4 knockouts were not
affected in their survival and lived as long as the wild-type controls; the experiment
was stopped after 250 days. Mice that were additionally carrying a Smo mutation
developed MB within the first 100 days of life and mostly died between P80 and
P150 (with median survival of 104 days for Math1-creERT2::Tcf4+/+SmoM2-YFPfl/+,
114 days for Math1-creERT2::Tcf4fl/+SmoM2-YFPfl/+, and 114 days for Math1-
creERT2::Tcf4fl/flSmoM2-YFPfl/+).
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There was no significant difference in survival for mice carrying a sole Smo mutation
and mice carrying an additional homozygous Tcf4 knockout. Interestingly, mice with a
heterozygous loss of Tcf4 seemed to survive for a longer period of time as seen in Fig. 22,
although median survival was equal to that of mice with a homozygous knockout of Tcf4.
Figure 23: Postnatal knockout of Tcf4 in SHH MB. H&E stain of SHH MB of
siblings at P76 (A-B) and P131 (C-D). Comparison of heterozygous and homozygous knockout
of Tcf4. The Tcf4 and Smo mutations were induced on P5 through tamoxifen injection. Mice
carrying a heterozygous knockout are shown to grow larger tumours.
Surprisingly, mice carrying a heterozygous Tcf4 knockout were growing bigger tumours
compared to mice with a homozygous loss (Fig. 23). A different experiment, performed
by another group member (Jasmin Ohli), measured the relative tumour area in the vermis
and the hemispheres and found that mice with a heterozygous loss of Tcf4 exhibited
the biggest tumours (data not shown). This independent effort found that a postnatal
loss of Tcf4 induced through a tamoxifen injection on day 5, either heterozygous or
homozygous, causes significantly bigger tumours compared to a Smo mutation alone
(data not shown). These results are yet another indication that Tcf4 functions as a
tumour suppressor and inhibits proliferation and tumour growth postnatally.
Currently, proliferation rates of granule cells in Math1-creERT2::Tcf4+/+SmoM2-YFPfl/+,
Math1-creERT2::Tcf4fl/+SmoM2-YFPfl/+ and Math1-creERT2::Tcf4fl/flSmoM2-YFPfl/+
are examined by another group member (Malte Hellwig) for further investigation and
comparison to the prenatal Tcf4 knockouts in SHH MB.
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The aim of this project was the investigation of the role of transcription factor 4 in
cerebellar development and its influence on initiation and growth of Sonic hedgehog
associated medulloblastoma. The function of TCF4 has been subject to different research
projects in the recent years, mainly focusing on the different diseases associated with
TCF4, understanding their molecular backgrounds and finding new treatment strategies
(see Section 1.1, p. 1). This thesis, for the first time, addresses the role of TCF4 in
medulloblastoma and describes in more detail its importance for cerebellar development.
The obtained results provide evidence that TCF4 exhibits different functionality at
different developmental stages and its loss affects cells in opposite ways, depending on
the time of knockout, i.e. prenatal versus postnatal knockout.
One of the main obstacles that had to be faced throughout the project was the
absence of a suitable anti-TCF4 antibody to confirm the correct recombination in the
knockout mice used. Even though several antibodies were tested, only one was available
that was proven to work. This anti-TCF4 antibody unfortunately binds to the AA
sequence 468-525 which lies before the loxP sites (Fig. 32, Appendix, Anti-TCF4 Sigma).
This antibody could be used for in vitro experiments to visualize the presence of the
TCF4 protein in cells and tissues. However, it could not be used to verify the absence
of TCF4 in granule cells after recombination, as the translated TCF4 protein from
the knockout mice is only missing its functional domain and still expresses the domain
detected by this specific anti-TCF4 (AA 468-525). Unfortunately, other approaches to
test for recombination, such as quantitative PCR or western blot analysis, also failed to
work. Although it was not possible to show the correct recombination for the duration
of the project, the distinct features exhibited by the mice and the obtained results are
evidence that recombination was successful and the findings indeed do result from a loss
of TCF4. To avoid this problem in the future, other mouse models, such as the one
generated by Skarnes et al. (2011) could be used; here, recombination is visualized by the
expression of LacZ. Another approach would be to generate a new antibody targeting an
epitope within the loxP sites.
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4.1 Importance of TCF4 in cerebellum development
The present work highlights the importance of TCF4 for correct formation and structure
of the cerebellum during brain development; illustrating that the loss of TCF4 causes
severe alterations in the cerebellum (Fig. 16). The findings described in regard to the in
vivo experiments in hGFAP-cre::Tcf4fl/fl mice (Section 3.5), demonstrate that a prenatal
homozygous loss of Tcf4 in mice leads to a significant decrease in cerebellar volume,
caused by a decrease in proliferation and an increase in apoptosis (Fig. 13 and 17). The
obtained results furthermore provide evidence that the observed structural alterations are
caused by the failed migration of granular cells from the EGL to the IGL (Fig. 18).
4.1.1 Anatomical alterations and correlations to PTHS in Tcf4 -
deficient mice
Through the investigation of the newly generated hGFAP-cre::Tcf4fl/fl transgenic mice,
it was possible to gain a good insight into the pathologies caused by a prenatal loss of
Tcf4, i.e. the anatomy of the whole mouse body in general and the micro-anatomy of
the cerebellum in specific. The decrease in body and brain weights and the structural
alterations detected under the microscope became more distinct with time and could
properly be observed starting from P14 (Fig. 13). Evidence was provided that an increase
in apoptosis and a decrease proliferation led to the significant differences in the measured
weights (Fig. 17). In a similar approach, Flora et al. (2007) demonstrated that Tcf4−/−
mice have a substantially reduced number of neurons in the pontine nucleus on P0.
Moreover, the onset of postnatal microcephaly in mice at P14 correlates with findings
from PTHS patients, where half of the patients develop a microcephaly during the first
twelve months of life and mostly before 1.5 years of age (Peippo and Ignatius, 2011).
According to Dutta and Sengupta (2016), one human year corresponds to roughly nine
mice days, so that 1.5 human years correspond to two weeks in the life of a mouse.
Apart from the microcephaly, case reports of PTHS patients have shown that similar
to the herein described mouse model, PTHS patients are smaller in size and height in
comparison to their peers (Taddeucci et al., 2010). In total, postnatal growth retardation
is seen in 25 % of PTHS patients (Peippo and Ignatius, 2011).
Measuring mice and brain weights was a useful first step to obtain an estimate on
the influence of Tcf4 on the development and growth of the whole body in general and
the cerebellum in particular. Interestingly, although the measurements described in this
work did only show significant differences for homozygous knockouts compared to WT
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mice for absolute brain weights, Thaxton et al. (2018) identified significant differences for
brain and body weights in heterozygous knockouts in four different mouse models. Two
of their mouse models utilize the same conditional Tcf4 knockout used for this project,
however, in combination with different promoters under which the Cre recombinase is
expressed. The differences seen in the heterozygotes could thus arise from the fact that
the Actin and Nestin promoters used by Thaxton et al. (2018) become active around
E10.5 in the brain (Cheng et al., 2004; Bertola et al., 2008), compared to hGFAP which
becomes active only at E13.5 (Zhuo et al., 2001). In addition, Thaxton et al. (2018)
measured the weights in adult mice aged P70-90, which indicates that stronger effects
regarding (brain) weights might also be expected in the hGFAP-cre::Tcf4fl/fl mouse at
later stages.
For an even more detailed analysis, mice could be weighed and measured on a
daily basis and not only the weights, but also the volumes of mice brains could be
analysed. Getting more frequent measurements, additional to the three time points (P7,
14 and 21), will also provide a better estimate as to when exactly do brain weights start
decreasing, i.e. when does the increased apoptosis and decreased proliferation start.
Moreover, growth curves could then be calculated for a better statistical analysis.
Another interesting aspect to evaluate is the hippocampal volume as very recently
performed by Jung et al. (2018). The group measured the hippocampal volume and
cortical diameter following a Tcf4 knockout using the Tcf4LacZ mouse and identified a
significantly reduced hippocampal volume in heterozygous mice.
The alterations observed in mouse brains on P14 and especially P21 correlate well
with the MR images from PTHS patients and the findings made by other groups (see Sec-
tion 3.5.3). Comparing the anatomical structure of mouse brains of hGFAP-cre::Tcf4fl/fl
mice with those of Pitt-Hopkins patients, a lot of similarities were identified, giving
validation to the idea that this mouse model can be used to investigate CNS changes
in Pitt-Hopkins syndrome, e.g. microcephaly, cerebellar hypoplasia, alterations of the
hippocampus (Fig. 14, 16, and 19). However, these distinct features can only be found in
mice carrying a homozygous knockout, whereas Pitt-Hopkins syndrome is defined as the
haploinsufficiency of TCF4, i.e. a heterozygous knockout. Furthermore, the knockout of
TCF4 occurs with the activation of hGFAP which is around day E13.5 in multi-potential
neuronal stem cells and thus only affects a subset of cells (Zhuo et al., 2001); which stands
in contrast to PTHS, a germline mutation of TCF4, where all cells are affected. To prove
that the newly introduced transgenic mouse model is still suitable to function as a model
for Pitt-Hopkins syndrome, further research involving some behavioural and learning
52
4.1 Importance of TCF4 in cerebellum development
ability tests need to be carried out. This type of tests have already been performed in
the Tcf4+/− mice by Kennedy et al. (2016) and just recently by Thaxton et al. (2018). It
would therefore be of great interest to identify whether the hGFAP-cre::Tcf4fl/fl mouse
exhibits similar features and can be used as an additional model alongside the already
published ones.
4.1.2 Migratory deficits in the cerebellar cortex of Tcf4 -
deficient mice
Besides proposing an explanation for the known differences in body and brain weights
in Tcf4 -deficient mice, that have already been published by other groups, this project
identified new structural alterations in the cerebellum that have not yet been addressed.
The results presented in this work provide evidence that (part of) the newly ob-
served histological alterations in mice with a homozygous loss of Tcf4 are based on
deficits in migration of granule cells from the EGL to the IGL (Fig. 18). Under normal
circumstances, granule cells migrate into the inner regions of the cerebellar cortex
alongside the radial fibres of the Berman glia. Other processes, such as the degradation
of cellular matrix, the formation of proliferative premigratory zones, and forms of
chemotaxis, are also know to be involved in the migration (Edmondson and Hatten,
1987; Be´nard et al., 2015). As the granule cells in Tcf4 -deficient mice fail to migrate into
the IGL, it is tempting to hypothesize that not only the granule cells themselves but also
the glia and the processes involved in the migration are affected by a loss of Tcf4 and
contribute to the observed phenotype.
A tentative evidence for this hypothesis comes from the comparison of the effects of a
Tcf4 knockout under the hGFAP promoter and the Math1 promoter (Fig. 16 and 29).
HGFAP-cre::Tcf4fl/fl mice clearly exhibit more severe alterations in comparison to the
Math1-cre::Tcf4fl/fl mice which can be explained by the fact that more cell types are
affected by a knockout under the hGFAP promoter (see Section 1.4.5). A closer look
into the functional changes of other affected cell lines and processes might then lead to a
more comprehensive understanding of the impact of Tcf4 on granule cell migration and
the consequences that arise from its loss. The idea that the PTHS phenotype could be
due to migratory deficits has already been proposed by Peippo and Ignatius (2011) as
they write ”intellectual disability, breathing abnormalities and epilepsy could be due to
aberrant migration of specific groups of cortical neurons...”.
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Also Flora et al. (2007) demonstrated that a homozygous loss of Tcf4 can cause
disruption and delay in migration by revealing that neuronal precursors ”were unable to
reach the pontine nucleus region”. Moreover, Chen et al. (2016) have recently shown
that ”in utero suppression of Tcf4 arrest[s] neuronal migration” and that Tcf4 ”controls
neuronal migration of the cerebral cortex through regulation of Bmp7”. These results
are in accordance with the findings of the present work and it would thus be of great
interest to examine if an upregulation of Bmp7 can also be observed in the neurons of
the cerebella of the mice used for this project.
4.2 Comparison of the PTHS mouse models
This thesis introduces a new mouse model for Pitt-Hopkins syndrome. Contrary to the
ones already published, it is the only one that shows a viable homozygous knockout
(Kennedy et al., 2016; Jung et al., 2018; Thaxton et al., 2018). With its distinct
phenotype, the hGFAP-cre::Tcf4fl/fl mouse can ideally be used to study CNS alterations
following a homozygous loss of Tcf4 in detail.
Currently, six different PTHS mouse models are published, comprising different
kinds of knockouts such as permanent and inducible knockouts and whole gene deletions,
deletions of exons and point mutations, with all of the published mice modelling a
heterozygous knockout as seen in PTHS (Table 3).
The first mouse to be examined as a model for PTHS was the Tcf4+/− mouse. It models
a germline mutation, a heterozygous loss of Tcf4, as generally found in patients suffering
from Pitt-Hopkins syndrome (Zhuang et al., 1996; Kennedy et al., 2016). These mice
harbour a behavioural phenotype and also the GI phenotype found in PTHS patients
(Grubiˇsic´ et al., 2015). Intriguingly, the CNS phenotype as well as microcephaly and
postnatal growth retardation are not present; and as such, the mouse fails to model
major characteristics of PTHS (Kennedy et al., 2016).
Jung et al. (2018), using the Tcf4LacZ mouse originally generated by Skarnes et al. (2011),
were able to show a microcephaly arising due to a heterozygous knockout of Tcf4 and a
CNS phenotype similar to but not as distinct as seen in the hGFAP-cre::Tcf4fl/fl mouse.
The main focus during the examination of the Tcf4LacZ mouse was on the cerebrum and
less on the cerebellum. Interestingly, Jung et al. (2018) report that the Purkinje cell
layer exhibits the highest TCF4 expression in the cerebellum, which stands in contrast
to the hGFAP-cre::Tcf4fl/fl mouse, where expression of TCF4 in the Purkinje cell layer
was not detectable and the highest expression was seen in the granule cells (Fig. 15). A
behavioural phenotype was not examined in the Tcf4LacZ mouse (Jung et al., 2018).
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Table 3: Comparison of the PTHS mouse models. Essential features of published PTHS mouse models in comparison to the Tcf4
model introduced in this work. Genotypes are given as stated in the respective publications. Description is given as CNS = central, het
= heterozygous, hom = homozygous, KO = knockout, GI = gastrointestinal, N/A= not applicable, PGR = postnatal growth retardation.
Features are given as ’present’ and ’not present’ if mentioned in the papers and as ’not examined’ if not mentioned in the respective
literature. The label ’not applicable’ is given if the genotypes do not allow examination of the characteristic. CNS phenotype describes
alterations to the structure and anatomy of the CNS as mentioned in some of the publications, whereas microcephaly describes the general
finding of decreased volume of the brain.
Mouse Model Tcf4+/− Tcf4lacZ/WT Tcf4fl/+::Actin-cre Tcf4fl/+::Nestin-cre Tcf4R579W Tcf4∆574−579 hGFAP-cre::Tcf4fl/fl
Reference Zhuang et al., 1996 Skarnes et al., 2011 Bergqvist et al., 2000 Bergqvist et al., 2000 Thaxton et al., 2018 Thaxton et al., 2018 Bergqvist et al., 2000
Kennedy et al., 2016 Jung et al., 2018 Thaxton et al., 2018 Thaxton et al., 2018 Schu¨ller laboratory (this work)
Knockout het Tcf4 KO het Tcf4 KO conditional het Tcf4 conditional het Tcf4 het Tcf4 mutation, het Tcf4 mutation, conditional hom Tcf4 KO
KO, pan-cellular KO, CNS specific non-functional TCF4 non-functional TCF4 in cerebellar cell types
CNS phenotype not present present not examined not examined not examined not examined present
Microcephaly not present present not present present present present present
PGR not present not examined present present present not present present
Behavioural phenotype present not examined present not examined present not examined not examined
GI phenotype present not examined not examined N/A not examined not examined N/A
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Thaxton et al. (2018) generated a total of four different mouse models, with two of the
models using the Tcf4fl/fl mouse from Bergqvist et al. (2000) that was also used for the
hGFAP-cre::Tcf4fl/fl mouse in the present project. Thaxton et al. (2018) expressed the
Cre recombinase under two different promoters, Actin to create a pan-cellular knockout
and Nestin to create a CNS-specific knockout of Tcf4. With these two mouse models,
Tcf4 is knocked out in a different set of cells. Both models were solely investigated
as heterozygous knockouts and as such showed a post-natal growth retardation. Addi-
tionally, the Tcf4fl/+::Actin-cre mouse presented with a behavioural phenotype but no
microcephaly, and the Tcf4fl/+::Nestin-cre mouse presented with a microcephaly, the
behavioural phenotype was not investigated (Thaxton et al., 2018). This suggests that
the time of knockout and the cell types that are affected have different influences on the
phenotype.
Thaxton et al. (2018) generated two more mice. The Tcf4R579W mouse, modelling the
most common PTHS mutation in humans (in humans it is R580W, Whalen et al., 2012)
and the Tcf4∆574−579 mouse, an in-frame deletion which was generated accidentally.
Both showed a microcephaly; the Tcf4R579W furthermore presented with a post-natal
growth retardation and a behavioural phenotype. All mutant mice were investigated as
heterozygous knockouts only, since homozygous knockouts resulted in early mortality
(Thaxton et al., 2018).
In comparison, the hGFAP-cre::Tcf4fl/fl mouse models a conditional homozygous
knockout of Tcf4 in the CNS, starting from about E13.5 (Zhuo et al., 2001). It was
demonstrated that the hGFAP-cre::Tcf4fl/fl mouse mimics the specific anatomical
alterations reported in the CNS of PTHS patients very well (Section 3.5.3). The model
described in this work also exhibits a microcephaly and a post-natal growth retardation
as seen in PTHS (Peippo and Ignatius, 2011). Nevertheless, hGFAP-cre::Tcf4fl/fl mice
only model a loss of Tcf4 in the CNS and can therefore not be used to examine other
features of this disorder. A behavioural phenotype has not yet been investigated in the
hGFAP-cre::Tcf4fl/fl mice.
To summarise, all present mouse models resemble Pitt-Hopkins syndrome in one
way or another, with none of them featuring all characteristics of the syndrome.
Especially the epilepsy and breathing abnormalities have not been described. The
hGFAP-cre::Tcf4fl/fl mice is exceptional regarding the fact that it is the only model that
produces viable offspring following a homozygous knockout and it clearly has the most
distinct CNS phenotype, with anatomical alterations not seen or described in any of the
other models. This mouse model can therefore be used to investigate a homozygous Tc4
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knockout in the CNS in detail, giving not only rise to investigations of PTHS but the
function and importance of Tcf4 for CNS development in general. Further investigation
of this model will clarify whether a behavioural phenotype is present. Moreover, it will
be interesting to determine which cell types are responsible for the different features
observed in PTHS and the respective mouse models. It is also of great interest to identify
the cell line and the time of knockout that lead to the early mortality in homozygous
Tcf4 knockouts.
4.3 Role of TCF4 in SHH medulloblastoma
Kool et al. (2014) reported that somatic TCF4 mutations can be found in 14 % of
adult SHH MB patients, sparking interest in the question what role does TCF4 play in
medulloblastoma growth and progression. The herein obtained results now strengthen
the hypothesis that TCF4 functions as a tumour suppressor in postnatal development
(Fig. 7, 9, and 10). Herbst et al. (2009b) were the first to identify TCF4 as a potential
tumour suppressor, demonstrating that TCF4 ”induces cell cycle arrest via p21Cip1”.
However, a definite ’label’ for TCF4 is yet to be determined as other findings suggest
that TCF4 shows oncogenic potential (Mologni et al., 2010; Appaiah et al., 2014). Even
Kolligs et al. (2002) initially thought TCF4 was exhibiting oncogenic potential before
Herbst, one of the group’s members, discovered TCF4 ’s tumour-suppressing nature
(Herbst et al., 2009a).
The analysis of the data available on human MB revealed that high TCF4 mRNA
levels improve the overall survival of patients with SHH MB (Fig. 7). Similarly, Brandl
et al. (2015) demonstrated that high protein levels of TCF4 are correlated with a better
outcome for patients with colorectal carcinoma, providing evidence that TCF4 exhibits
characteristics of a tumour suppressor.
The hypothesis that TCF4 functions as a tumour suppressor was further confirmed
during the experimental analysis of TCF4 mutants in this project (Fig. 9). The findings
showed that introducing WT TCF4 into a MB cell line (DAOY) significantly decreases
cell proliferation. Unfortunately, the DAOY cell line was originally obtained from a
young boy (Jacobsen et al., 1985) and is therefore not an adult SHH MB. Ideally, a MB
cell line derived from an adult SHH MB should be used for this type of experiment.
However, as the four currently established SHH MB lines were all obtained from children,
there is no adult cell line available (Ivanov et al., 2016).
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Besides, although TCF4 mutations have solely been found in adults, the effects that the
mRNA levels have on the survival of patients, and the raised mRNA levels in general,
were seen in all three SHH MB age groups; i.e. infant, child, and adult MB (Fig. 6). In
agreement with the described results, Kim et al. (2008) demonstrated that the expression
of TCF4 can decrease cell growth in a gastric cancer cell line and that silencing of TCF4
plays a role in tumour formation.
Apart from the in vitro experiments performed in a tumourous environment, the
in vivo effects of a Tcf4 knockout seen in mice with SHH MB were very similar to those
obtained in mice with a sole Tcf4 knockout (Fig. 17 and 21), meaning that a prenatal
Tcf4 knockout increased the number of cells undergoing apoptosis. In what ways a
postnatal knockout of Tcf4 alters proliferation and apoptosis rates in the SHH MB
mouse model, has yet to be determined. Nevertheless, an additional loss of Tcf4 did
not change survival rates of both SHH MB mouse models analysed (Fig. 20 and 22),
regardless of a prenatal or postnatal loss of Tcf4. These findings suggest that the effects
of a Tcf4 knockout regarding cell growth are independent of the Smo mutation and the
development of SHH MB. All experiments carried out in respect to SHH MB provide
evidence for TCF4 functioning as a tumour suppressor when knocked out postnatally.
4.4 Prenatal versus postnatal TCF4 knockout
The results presented in this work suggest that the role of TCF4 is time-sensitive,
as the obtained findings point out that Tcf4 influences granule cells in different ways
depending on the time of the knockout. While a prenatal knockout of Tcf4 increases
apoptosis and decreases proliferation, a postnatal Tcf4 loss leads to a significant increase
in proliferation (Fig. 10, 17, and 23).
The observation that a gene can have opposing roles during development is not
new; in fact, very similar results regarding another gene have just been published by
Merk et al. (2018). Here, the role of the factor CREBBP, another gene identified to
have somatic mutations in SHH MB and that is associated with the neurodevelopmental
disorder Rubinstein-Taybi syndrome, was reported to have time-sensitive effects.
To get a better understanding of these different influences, knockouts at additional time
points should be examined. As mentioned before, mice with a total Tcf4 knockout
(Tcf4−/− mice) are not viable and are mostly stillborn (Flora et al., 2007), providing
evidence that Tcf4 is essential for survival.
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A study performed by de Pontual et al. (2009), examining the expression pattern of Tcf4
during early development, could be used to determine suitable points to knock out Tcf4
and investigate how cells and the whole organism react to its loss. This might solve the
question as to when a Tcf4 knockout leads to an upregulation in apotosis and when in
cell proliferation.
The relevance of the different occurrences of a TCF4 loss are also demonstrated
by the fact that a germline mutation in TCF4, as seen in PTHS, does not increase the
tumour incidence in those patients, since there is only one case reported so far in which
a PTHS patient developed cancer (Zweier et al., 2007).
Having a closer look into the different functions of TCF4 depending on the time of
knockout will help shed more light onto its different roles in neurodevelopment and
neuromaintenance, and identify whether PTHS is solely a neurodevelopmental disorder
or if the lack of TCF4 throughout adult life contributes to the PTHS phenotype.
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The Tcf4 knockout mouse model hGFAP-cre::Tcf4fl/fl presented in this thesis is a
suitable model to investigate a homozygous Tcf4 knockout in vivo. With its similarity
to PTHS, it can be used to examine this rare neurodevelopmental disorder. The
hGFAP-cre::Tcf4fl/fl mouse is furthermore of special interest, as it is the only PTHS
mouse model to date that is viable as a homozygous knockout and as such shows a very
distinct phenotype not observed in any of the other published models.
The results obtained for this project point out that the function of TCF4 is time-
sensitive with its effects differing depending on whether the knockout occurs prenatally
or postnatally. More precise, there is a difference in the effects between a germline and
a somatic TCF4 mutation. A prenatal knockout of Tcf4 leads to microcephaly most
likely caused by a decrease in proliferation and an increase in apoptosis in granule cells.
It furthermore leads to migratory deficits in granule cells with its molecular cause still to
be determined. It is tempting to propose that the glia plays an important part in this
phenomenon. A postnatal knockout on the other hand causes an increase in proliferation
in vitro.
The investigation of an acquired loss of TCF4 provided evidence for the protein to
function as a tumour suppressor in medulloblastoma, as overexpression of TCF4 improves
overall survival rates in SHH MB. Moreover, the expression of wild-type TCF4 is able to
decrease proliferation in a medulloblastoma cell line.
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The findings presented in this thesis contribute to the understanding of the function of
TCF4. However, further work is required for a more comprehensive picture of TCF4, its
role in CNS development, and its influence on SHH MB. Especially the different effects
of prenatal and postnatal TCF4 knockouts should be addressed in more detail. Sweatt
(2013) already raised the question as to how different the effects of TCF4 during develop-
ment and adult stages are. The author explained that the PTHS symptoms are caused by
the TCF4 knockout during the developmental stages but what happens in the adult brain
remains unclear: ”It is unclear whether PTHS is caused exclusively by disruption of TCF4
function during development or whether loss of TCF4 in the mature CNS might also
contribute to neurobehavioral and cognitive dysfunction in PTHS patients” (Sweatt, 2013).
Apart from the time-dependent effects of TCF4, other aspects mentioned in this
thesis merit further investigation. For example, the development of the whole brain after
loss of TCF4 with special focus on the hippocampus should be observed more closely.
This would also give a better estimate as to how well does the herein introduced mouse
model mimic Pitt-Hopkins syndrome and in what ways can it be used to investigate this
rare disorder. Moreover, behavioural studies and cognitive testing of this mouse model
need to be carried out.
An even closer look into the cells and their behaviour itself, especially a better in-
vestigation of migration and formation of cells as well as the development of dendritic
arbours, will give a more comprehensive understanding in respect to the alteration
of the anatomical structure in the cerebellum and cerebrum. As described before,
this research should also include the role of the extracellular matrix and other cell
types involved in the migratory process, specifically the glia. The question of whether
”distinct cell populations may require different TCF4 dosages and whether there is cell
type-/region-specific vulnerability to pathologically altered TCF4 expression levels” (Jung
et al., 2018) should also be addressed in future research into TCF4.
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A next step in this context would then be to investigate the effects of reintroducing TCF4
following its earlier knockout and to determine if there is the possibility of rescuing the
phenotype. For example, by generating vectors using the foamy virus, which inserts its
genome solely in a subset of proliferating cells in the brain such as hippocampal neurons
(Counsell et al., 2018), the effect of reintroducing TCF4 in separate cell lineages could
be investigated.
Furthermore, the examination of effects of TCF4 knockouts in the adult brain, i.e. at
later time points than P5, would give more information about the function of TCF4 in
general and its role in the adult brain in specific. Sweatt (2013) already proposed that
”a new understanding of the role of TCF4 in the fully developed CNS might allow the
development of new therapeutic approaches to PTHS treatment based on restoration or
augmentation of TCF4 function after CNS development is largely finished”. In particular,
the inducible knockout system used in this project is ideally suited to investigate the
postdevelopmental brain in respect to TCF4 function.
Another question that has yet to be answered, is why the other two E-proteins,
E2A and HEB, are unable to compensate for the loss of function of TCF4 despite them
being conserved (Murre, 2005). Looking closer into the heterodimerisation partners and
identifying the partners that pair with the E-proteins across different cell types and
tissues will help to understand the mechanism behind the potentially different behaviour
of these E-proteins.
Regarding SHH MBs, further research into the impact of a postnatal TCF4 knockout
and the possibility of using TCF4 and its heterodimerisation partners for treatment of
this tumour entity is of great interest. Specifically the impact of introducing or activating
TCF4, as described in DAOY cells and seen in patients with high mRNA levels of TCF4,
should be investigated.
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7.1 Material
7.1.1 Appliances
Appliances Manufacturer Type
CO2 incubator Heraeus HercaCell 240
Fluorescence Microscope Olympus IX50 Mikroskop
Optical Microscope Olympus Olympus Bx50 Microscope
Spectrophotometer NanoDrop Technologies Nanodrop 1000
Sterile bench Thermo HERAsafe
7.1.2 Software
Software Manufacturer Type
Cell counts ImageJ ImageJ
Gel documentation Synoptics Limited Syngene Geldokumentationssystem
Microscope Software Olympus ColorView Soft imaging Systems
Statistical analysis GraphPad Prism 5.02 Software and
Prism 7.01 Software
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7.1.3 Chemicals
Substance Manufacturer Type
Blocking reagent Invitrogen I-Block blocking reagent
BrdU Sigma-Aldrich
DAPI Roth 4´,6-Diamidin-2-phenylindol
DEPEC Water Roth
DMEM PAN
DMEM-F12 Invitrogen
DNA Ladder Promega
DNAse Invitrogen
DPBS Invitrogen
FCS Invitrogen
Glucose Sigma D(+)-Glucose
Glutamax Invitrogen
HBSS Gibco
HEPES Sigma
Klenow Fragment Thermo Scientific
Leibovitz Invitrogen
Ligase Thermo Scientific T4 DNS Ligase
Loading Dye Promega 6x Loading Dye
Lysozyme Merck
N2 supplement Invitrogen
NanoJuice Novagen NanoJuiceTM Tranfection
Reagent and Kits
Opti-MEM Gibco
Pen/Strep Invitrogen Penicillin/Streptomycin 100x
PLO Sigma Poly-L-ornithine
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Substance Manufacturer Type
Polymerase Agilent Herculase II Fusion
DNA Polymerase
Tamoxifen SigmaAldrich
TransIT-2020 Mirus TransIT®-2020
Tranfection Reagent
Trizol Invitrogen
Trypsin-EDTA Sigma
X-tremeGENE Roche X-tremeGENE HP
7.1.4 Kits
Kit Manufacturer Type
Gel extraction Qiagen QIAquick Gel Extraction Kit
Immunostaining Dako System-HRP DAB-Kit
MaxiPrep Qiagen QIAprep Spin Midi/MaxiPrep Kit
MiniPrep Qiagen QIAprep Spin MiniPrep Kit
Protein concentration Sartorius Vivaspin6
Protein purification Macherey Nagel Protino Ni TED 2000
NiDA 200 packed columns Kit
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7.1.5 Antibodies
Antibody Manufacturer No.
Anti-BrdU Sigma 11170376001
Anti-Caspase-3 (Asp175) Cell Signaling Tech 9664
Anti-GFP (mouse) Invitrogen A11120
Anti-GFP (rabbit) Santa Cruz sc-8334
Anti-PAX6 DSHB
Anti-phospho-Histone-H3 Cell Signaling Tech 9706S
Anti-TCF4 Sigma HPA025958
Anti-Rabbit IgG H&L Invitrogen A11034
(Alexa Fluor® 488)
Anti-Mouse IgG H&L Invitrogen A11029
(Alexa Fluor® 488)
Anti-Rabbit IgG H&L Invitrogen A11035
(Alexa Fluor® 546)
Anti-Mouse IgG H&L Invitrogen A11003
(Alexa Fluor® 546)
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7.1.6 Plasmids
Plasmid Size Charateristics Use
pcDNA3 5.4 kb site directed
mutagenesis
pN8-gag-pol Backbone: pN8-epsilon packaging plasmid
pN8-VSV-G Backbone: pN8-epsilon envelope plasmid
MSCV-IRES-GFP 6.5 kb expresses GFP CGNP, site directed
mutagenesis
MSCV-Cre-IRES-GFP 8.4 kb expresses CRE and GFP CGNP
Modified Plasmid Size Characteristics Use
pcDNA3-ITF2B 7.4 kb backbone: pcDNA3, site directed
WT TCF4 mutagenesis
IRES-GFP-TCF4 8.5 kb
backbone: IRES-GFP,
WT TCF4
DAOY transfection
IRES-GFP-TCF4 V613F 8.5 kb
backbone: IRES-GFP,
mutation V613
DAOY transfection
IRES-GFP-TCF4 216del 8.5 kb
backbone: IRES-GFP,
mutation 216 219del
DAOY transfection
IRES-GFP-TCF4 451del 8.5 kb
backbone: IRES-GFP,
mutation 451 453del
DAOY transfection
IRES-GFP-TCF4 R157X 8.5 kb
backbone: IRES-GFP,
mutation R157X
DAOY transfection
IRES-GFP-TCF4 R174X 8.5 kb
backbone: IRES-GFP,
mutation R174X
DAOY transfection
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7.1.7 Mouse strains
Strain Characteristics Publication
C57/Bl6 WT mouse
FBV WT mouse
hGFAP-cre
expression of Cre recombinase
under the hGFAP promoter
Zhuo et al., 2001
Math1-cre
expression of Cre recombinase
under the Math1 promoter
Matei et al., 2005;
Schu¨ller et al., 2007
Math1-creERT2
inducible expression
of Cre recombinase
Machold and Fishell, 2005
SmoM2-YFPfl/fl
conditional mutation
of Smo
Mao et al., 2006
Tcf4fl/fl conditional knockout of Tcf4 Bergqvist et al., 2000
Conditional knockouts
hGFAP-cre::SmoM2-YFPfl/+ activation of SHH signalling pathway
hGFAP-cre::Tcf4fl/fl knockout of Tcf4 under
the hGFAP promoter
hGFAP-cre::Tcf4fl/flSmoM2-YFPfl/+ activation of SHH signalling pathway
and loss of Tcf4
Math1-cre::Tcf4fl/fl conditional knockout of Tcf4
under the Math1 promoter
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Inducible knockouts
Math1-creERT2::SmoM2-YFPfl/+ inducible activation of SHH
signalling pathway
Math1-creERT2::Tcf4fl/fl knockout of Tcf4 under
the Math1 promoter
Math1-creERT2::Tcf4fl/flSmoM2-YFPfl/+ inducible activation of SHH
signalling pathway and loss of Tcf4
7.1.8 Self-made buffers and media
Cell culture medium Cell culture medium for permanent cell lines was DMEM with
added 10 % FCS, 1 % glutamax, 1 % penicillin/streptomycin, and 1 % HEPES buffer.
SOC Medium (Super Optimal Broth with Catabolite repression) For the production
of 100 ml of SOC medium, 0.5 g yeast extract, 2 g peptone, 1 ml 1M MgSO4, 1 ml 1M
MgCl2, 0.05 g NaCl, and 0.25 ml 1M KCl were mixed in 100 ml of ddH2O and the solution
was autoclaved. Then, 2 ml of sterile filtered glucose was added (1.8015 g in 10 ml =
1 M). The medium was aliquoted in 15 ml falcon tubes and stored at - 20 °C.
2× HBS (HEPES buffered saline) For 200 ml of 2× HBS, 3.2 g NaCl, 40 mg Na2HPO4,
540 mg glucose, and 2 g HEPES were diluted in 200 ml ddH2O. The pH was adjusted to
7.1 using HCl. The 2× HBS was sterile filtered with a 0.2 µm syringe filter and aliquots
of 1.5 ml were stored at -20 °C.
2.5 M CaCl2 For the 2.5 M CaCl2 solution, 36.75 g of CaCl2×2H2O were diluted in
100 ml of ddH2O, sterile filtered with a 0.2 µm syringe filter and aliqouts of 10 ml stored
at -20 °C.
Laird’s lysis buffer Lysis buffer consisted of 200 mM NaCl, 100 mT Tris-HCl adjusted
to pH 8.3, 5 mM EDTA, 0.2 % SDS and 200 µg/ml proteinase K in ddH2O.
TE buffer Tris-EDTA buffer solution consisted of 20 mM Tris-HCl adjusted to pH 8.3
and 1 mM EDTA in ddH2O.
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Sonic hedgehog protein Sonic hedgehog was produced by the laboratory technical
assistants. SHH expressing bacteria (BL21/pEXP-DEST-LRC4) were thawed and trans-
ferred to agar for overnight incubation at 37 °C. One single colony was picked the next day
for the production of SHH. Bacterial cells were then grown in LB (Luria Broth) medium
until an optical density (OD, 600) of 0.4-0.6 was reached. Expression of SHH was sub-
sequently induced using isopropyl β-D-1-thiogalactopyranoside (1 mM in LB medium).
Cells were pelleted and SHH was purified using the Protino Ni TED 2000 or NiIDA 200
packed column Kits from Macherey Nagel. The purified protein was concentrated 30-fold
using Vivaspin6 columns. SHH was stored in SHH storage buffer (5 mM Na2HPO4, 150
mM NaCl in ddH2O) with 0.5 mM dithiothreitol at -80 °C. Protein concentration was
determined via a BCA (bicinchoninic acid) assay.
Tamoxifen Tamoxifen was administered intraperitoneally at a concentration of
20 mg/ml. Mice were usually treated with 1 mg of tamoxifen (25 µg per gramm body
weight, i.e. 50 µl of 20 mg/ml solution). For the production of the solution, 100 mg
tamoxifen were dissolved in 100 µl of 100 % ethanol and shaken for 20 min at 55 °C.
900 µl corn oil were added and the mixture was shaken at 55 °C until almost dissolved.
The solution was then transferred into a 15 ml falcon flask containing another 4 ml of
corn oil, mixed and stored at 4 °C until usage.
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7.2 Methods
7.2.1 General molecular biological methods
7.2.1.1 Cloning and site directed mutagenesis
To determine the effects of introducing TCF4 to a TCF4 deficient medulloblastoma cell
line, plasmids containing WT TCF4 and several known TCF4 mutants found in SHH-
associated medulloblastoma were transferred separately into the DAOY cell line. Hereby,
the effect of TCF4 on cell growth as well as the left-over function of the different mutants
could be examined.
Preparation of TCF4 plasmids A pcDNA3 plasmid containing the human TCF4
sequence (isoform ITF-2B−) with an added HA-tag was received from the group of
Professor Frank Kolligs (LMU Munich).
For further use, the TCF4 sequence was cut out of the plasmid and cloned into the
MSCV-IRES-GFP backbone which was also used for the production of viral particles
(expression vector). The MSCV-IRES-GFP vector was kindly provided by Professor
David Rowitch (Cambridge). To cut the TCF4 insert, the plasmid had to be amplified
first. Therefore, transformation of plasmids was carried out using XL2 blue chemically
competent bacterial cells. The bacterial cells were thawed on ice, 100 ng of DNA was
added and incubated for 30 min on ice. The bacteria were then heat-shocked for 42 s
and subsequently incubated on ice for another 2 min. 500 µl of SOC medium was added
and the solution was incubated for 60 min on a shaker (250 rpm) at 37 °C. Cells were
plated onto an agar plate containing ampicillin as a selection marker and incubated at
37 °C overnight. Up to five single colonies were picked the next morning and incubated
separately for another night in liquid media (5 ml LB medium with ampicillin 1:1000)
for DNA preparation the next day. DNA preparation using mini columns was carried
out according to the manufacturer’s instruction (QIAprep Spin MiniPrep Kit, Qiagen)
and the DNA yield was determined using a Nanodrop, a UV/VIS spectrophotometer
measuring the concentration and quality of double stranded DNA.
The plasmid with its insert and the backbone (MSCV-IRES-GFP) were digested
using restriction enzymes and the fragments were transferred to an agarose gel to
separate the pcDNA3 backbone and the TCF4 insert. The DNA fragments could then
be extracted and purified using the QIAquick Gel Extraction Kit (Qiagen). For ligation,
a blunt-end ligation using the Klenow Fragment (ThermoScientific) was carried out, first
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filling in the 5’-overhangs on the insert and the backbone and then ligating the two
fragments with T4 ligase. The obtained plasmid was transformed into XL2 blue cells
and the newly cloned plasmid amplified and purified as described above. The purified
plasmid was then digested using restriction enzymes to verify ligation of backbone and
insert. To check for correct ligation, i.e. the orientation of the insert, the plasmid was
send off for sequencing (sequencing was done by Eurofins Scientific).
Site directed mutagenesis TCF4 mutants were generated through site-directed
mutagenesis using overlap extension polymerase chain reaction (PCR). For the later
transfection of the DAOY cell line, the plasmid MSCV-IRES-GFP was used as the
backbone, however, due to difficulties during the PCR steps, the mutants were generated
in the pcDNA3 plasmid, cut out and inserted into the MSCV-IRES-GFP backbone.
Figure 24: Principle for site directed mutagenesis. Modified after Heckman and
Pease (2007). For site directed mutagenesis, a first PCR (marked with 1) was performed using
Ffv (flanking primer forward) and Mrv (mutagenic primer reverse) and Mfv (mutagenic primer
forward) and Frv (flanking primer reverse) respectively to receive overlapping DNA fragments.
Mfv and Mrv carry the mutation shown in red. A second PCR (marked with 2) using only Ffv
and Frv was used to create a continuous DNA fragment carrying the mutation.
Design of mutants was mainly performed according to the protocol of Heckman and
Pease (2007) ”Gene splicing and mutagenesis by PCR-driven overlap extension”, with
small adjustments for the purposes of this experiment.
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For each mutant, two pairs of primers were used, all listed in Table 4, with one pair
introducing the mutation (mutagenic primers) and the second pair for amplifying the
whole insert (flanking primers). The introduction of the mutation was then done in two
steps.
Table 4: Primer sequences used for site directed mutagenesis. Primer name con-
tains the respective mutation. Flanking primers were designed for the pcDNA3 backbone
carrying recognition sites for EcoRI and XhoI respectively.
Primer Sequence in 5’ - 3’
216 219del fw CCTAGCTCCTTCGGCCATCACAGC
216 219del rv GCTGTGATGGCCGAAGGAGCTAGG
451 453del fw CATTCACTCATGCATCGTGAAGAT
451 453del rv ATCTTCACGATGCATGAGTGAATG
V613F fw CGGTGGCCTTCATCCTCAGTC
V613F rv GACTGAGGATGAAGGCCACCG
R157X fw CAATAATCCCTGAAGGAGGCC
R157X rv GGCCTCCTTCAGGGATTATTG
R174X fw CAAAGAAAGTTTGAAAAGTTCCTC
R174X rv GAGGAACTTTTCAAACTTTCTTTG
flanking primer fw GTACCGAGCTCGAATTCACC
flanking primer rv ATGCATGCTCGAGTCAGGC
First, the forward flanking primer and the reverse mutagenic primer and vice versa were
used in separate PCRs to create two DNA fragments carrying the mutation (Fig. 24).
The primer sequences of the mutagenic primers were designed so that the PCR amplicons
were overlapping. The products from the first PCR were purified and a second PCR was
performed, using only the two flanking primers, to create a continuous insert.
Normally, this insert would then be purified and ligated into the original back-
bone. In this specific case however, the mutation had to be introduced into a different
plasmid than the one of interest for the experiment. This was due to a repetitive
sequence in the MSCV-IRES-GFP plasmid producing a hairpin structure that the
DNA polymerase could not read. To solve this problem, the flanking primers had been
designed in a way that they also carried the sequences of the recognition sites for the
restriction enzymes EcoRI and XhoI, which are present in the multiple cloning site
of the MSCV-IRES-GFP backbone. Therefore, the inserts could be produced using
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the pcDNA3 backbone. The synthesised inserts were then purified, digested (using a
double-digest with the above mentioned enzymes), purified again, and ligated using a
sticky-end ligation with the MSCV-IRES-GFP backbone that had also been digested
with EcoRI and XhoI.
All plasmids were subsequently transformed into XL2 blue cells for DNA prepara-
tion. Yielded DNA was purified and location of insert was verified via restriction digest
and gel electrophoresis of obtained fragments. Purified plasmid DNA was send off for
sequencing (Eurofins) to check for correct mutations and insertion into the backbone.
The plasmids were then used for transfection of DAOY cells.
Figure 25: Example DNA and protein sequence of TCF4 mutant. Excerpt of
TCF4 (top) sequence and sequence of the TCF4 mutant R174X (bottom). Given are the DNA
sequences and the corresponding protein sequence. The triplett CGA (marked in red) coding
for the AA arginine (Arg) was changed to TGA, a stop codon (End).
7.2.1.2 Virus production
To compare the growth of Tcf4 deficient and Tcf4 sufficient cells, a knockout of Tcf4
in CGNP cell cultures was generated by transducing the cells with retroviral particles.
Two different viruses, containing either IRES-GFP or Cre-IRES-GFP, had therefore to
be produced and tested.
Retroviral particles were produced in Human Embryonic Kidney (HEK) cells via
a triple transfection with a packaging plasmid (pN8-gag-pol), an envelope plasmid
(pN8-VSV-G), and the MSCV-IRES-GFP or MSCV-Cre-IRES-GFP vector. The
MSCV-IRES-GFP and MSCV-Cre-IRES-GFP plasmid were kindly provided by Pro-
fessor David Rowitch (Cambridge).
Transfection was performed using the calcium phosphate method. The day before
transfection, HEK cells were plated onto 10 cm dishes at a confluency of 15-20 % in order
to achieve a confluency of 50-70 % 24 h later. The next day, medium was changed 1 h
prior to transfection. For the transfection itself, a total of 45 µg DNA, with 15 µg of each
plasmid, were mixed with TE buffer in an overall volume of 50 µl. 400 µl nuclease free
water and 50 µl of CaCl2 were added and the mixture vortexed. This solution was added
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dropwise to a new tube containing 500 µl of 2× HBS and incubated for 30 min at room
temperature (RT). The transfection reagents were then added dropwise into the media
of the cell culture dishes and incubated at 37 °C for a day. After 24 h and 48 h, the
HEK cells were observed under the fluorescence microscope to examine viral production.
Efficiency of transfection and viral production could easily be determined by estimating
the fraction of green fluorescent cells, since GFP was produced. The media containing
the viral particles was harvested 24 h and 48 h post transfection and subsequently filtered
through a 0.45 µm syringe filter to remove cell debris and any contamination. The virus
was then aliquoted and stored at -80 °C.
Before use on CGNP cultures, the virus was tested on HEK cells. Therefore, 24-well
plates were seeded with HEK cells. The next day, media was taken off and replaced
with 200 µl of media containing the virus and plates were incubated at 37 °C for 4 h.
The virus was then discarded, 500 µl of fresh media added to the wells and the HEK
cells again incubated at 37 °C. Efficiency of transduction was determined 24 h and 48 h
later by estimating the fraction of GFP-positive cells in the wells through fluorescence
microscopy.
7.2.1.3 Transfection of DAOY cells
The effects of WT TCF4 and TCF4 mutants on cell proliferation were tested on a
medulloblastoma cell line. DAOY cells were transfected with seven different plasmids
(the backbone alone, TCF4 WT, and five different TCF4 mutants, see Table 5) using
the MSCV-IRES-GFP vector. The transfection of DAOY cells was found to be not very
efficient, however, after testing several transfection reagents under different conditions,
the transfection reagent TransIT-2020 (MiruBio) was the most promising. Transfection
was first tested with calcium phosphate and later with the transfection reagents Fugene,
NanoJuice, and X-tremeGENE, all of which showed a transduction efficiency of around
5 %. To optimse the efficiency, several reagents from Mirus were tested and the Trans-IT
2020 reagent was found to have an efficiency in DAOY cells of about 25 %, which was
used for the following experiment.
The day before transfection, DAOY cells were plated in 24-well plates at a conflu-
ency of 40 %. 2 h prior to transfection, the medium was changed. For each well, the
transfection mixture was prepared as follows: To a tube filled with 50 µl of Opti-MEM
medium, 1.5 µg of the respective plasmid DNA and 1.5 µl of Trans-IT 2020 (vortexed
just before use) were added and mixed. The transfection mixture was incubated for
15-30 min at RT and then added dropwise to the well.
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The plates were incubated at 37 °C for two days. 48 h post transfection, the DAOY cells
were pulsed with BrdU (final concentration of 25 µg/ml) for 2 h and then the media
discarded. Cells were fixated with 4 % paraformaldehyde (PFA) and subsequently stained
for either BrdU and TCF4 or BrdU and GFP (see Section 7.2.4.2 for exact protocols).
The tranfected, fixated, and stained cells were observed under the fluorescence micro-
scope. Transfected cells were identified by their expression of GFP and proliferation
rates of BrdU-positive cells was compared between WT TCF4 and the different mutants.
Statistical analysis was done using chi-squared tests.
Table 5: Plasmids used for transfection of DAOY cells. The table lists all con-
ditions used for the transfection of DAOY cells. The WT TCF4 and mutant TCF4 were
inserted into the MSCV-IRES-GFP backbone, also used as a control. The names of the
respective plasmid are given and the mutation and functional domain are noted.
Plasmid Mutation and functional domain
no plasmid control
MSCV-IRES-GFP backbone as control
MSCV-IRES-GFP-TCF4 WT TCF4
MSCV-IRES-GFP-TCF4-R157X nonsense mutation in NLS
MSCV-IRES-GFP-TCF4-R174X nonsense mutation in NLS
MSCV-IRES-GFP-TCF4-216del deletion
MSCV-IRES-GFP-TCF4-451del deletion
MSCV-IRES-GFP-TCF4-V613F missense mutation in bHLH domain
7.2.2 Cell culture
Two types of cell cultures were used for this project. First of all, a primary cell culture
established from cerebellar granule neuron precursors of mice was used for the examination
of Tcf4 knockouts in vitro. Two immortalised cell lines, HEK 293T and DAOY cells, were
also used during the experiments. Whereas HEK cells were only used for purposes of
producing and testing retroviral particels, DAOY cells were needed to investigate effects
of TCF4 in an MB cell line in vitro. All cell lines were adherent, i.e. growing in monolayers.
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7.2.2.1 Cerebellar Granule Neuron Precursor Culture
To investigate the influence of a Tcf4 loss on cell growth in cerebella of mice in vitro, cell
growth in Tcf4 -deficient cerebellar granule neuron precursor cell cultures was examined.
For preparation of CGNP cultures, a 24-well culture plate was first plated with poly-
L-ornithine (PLO). Therefore, 12 ml phosphate buffered saline (PBS) were mixed with
100× stock of 1.5 mg/ml PLO in ddH2O and 500 µl PLO were added to each well. Plates
were stored at 4 °C overnight. Several media were needed for the CGNP cultures and
were prepared as follows: Hanks buffered saline solution (HBSS) was adjusted to a pH of
7.4 and 6 mg/l glucose was added. The solution was sterile filtered with a 0.2 µM filter
and aliquots of 50 ml were stored at 4 °C. A lysis buffer (papain/EDTA/Leibovitz) was
prepared by adding 20 µl papain and 5 µl EDTA to 2 ml Leibovitz medium.
For the culture medium, 50 ml DMEM-F12 were mixed with 500 µl of N2 supplement
(100× stock), 500 µl of 1x penicillin/streptomycin solution and 5 µl of 2.5 M KCl for a
final concentration of 0.25 mM KCl. A volume of 20 ml of the medium were transferred
to another flask and 2 ml of foetal calf serum (FCS), which had been heat inactivated at
56 °C for 30 min previously, was added (total of 10 % FCS).
Cerebella of Tcf4fl/fl mice aged P5 to P7 were dissected in HBSS and stored in
15 ml centrifuge tubes in HBSS on ice until further use. Cerebella were centrifuged at
800 rpm for 5 min at 4 °C, the HBSS discarded and 1 ml of lysis buffer added, and the
cerebella incubated for 10 min at 37 °C in a water bath. The papain in the lysis buffer
was subsequently inactivated with 1 ml of the prepared culture medium containing FCS.
Cerebella were centrifuged at 1,500 rpm for 5 min. The solutions was aspirated and
replaced with 5 ml of HBSS/glucose. The cerebellar fragments were gently pipetted up
and down to break up the pellet and spun again at 1,500 rpm for 5 min. After aspiration
of the HBSS/glucose, the pellet was re-suspended in 1 ml HBSS/glucose, broken down
and spun as before. The HBSS/glucose was discarded and 2 ml of culture medium with
FCS were added to the cells. Then, the cells were counted in a Neubauer cell count
chamber and the volume of the medium was adjusted to a total of 1 million cells per ml.
In the meantime, the PLO plated 24-well plates were washed twice with 500 µl of PBS
per well and subsequently 500 µl of the cell culture medium containing the cerebellar
precursors were added to each well (total of 500,000 cells/well). Cell culture plates were
stored in a CO2 incubator at 37 °C, 5 % CO2, and 95 % air humidity for 6-12 h. The
cell culture medium was carefully removed and fresh culture medium with added SHH
protein at a final concentration of 3 µg/ml SHH was added. The cells were cultured in
this medium for 24 h. Sonic hedgehog protein causes all cells, except granule cells, to
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leave the cell cycle during the 24 hours cultivation in this media, hence solely granule
precursors will proliferate under these circumstances.
In a next step, the media containing SHH was taken off and 200 µl of media con-
taining the viral particles - either sole IRES-GFP or Cre-IRES-GFP - was added
and cells incubated for 4 h. These retroviral particles only infect cells undergoing
proliferation, other than lentiviral particles which are able to infect all cells, which
ensures that only granule cells were transduced. The Cre-IRES-GFP virus expresses the
Cre recombinase to cut out Tcf4 using the loxP sites (see Section 7.2.3.1) generating the
Tcf4 KO. Medium was then removed and fresh medium with SHH protein was added for
another 24 h. Finally, 1.25 µl of BrdU (10 mg/ml) for a final concentration of 25 µg/ml
was added to the medium for 2 h. Subsequently cells were fixed with 4 % PFA and
stained for BrdU and GFP (see Immunofluorescence).
7.2.2.2 Immortalised cell lines
All cell lines were cultivated in DMEM supplemented with 10 % FCS, 1 % glutamax,
1 % penicillin/streptomycin, and 1 % HEPES and grown in a CO2 incubator at 37 °C,
5 % CO2, and 95 % air humidity. The general handling of the cell lines was as follows:
Cryovials containing the frozen cells were taken from the nitrogen tank, where they were
stored, and thawed quickly in a water bath at 37 °C. Cells were then washed in 7 ml pre-
warmed cell culture medium by resuspending and subsequent centrifugation to remove
DMSO (dimethyl sulfoxide). The washed cells were transferred to a T-25 cell culture
flask containing 5 ml of pre-warmed medium. The flask was gently shaken in order to mix
the cells equally in the medium and incubated as described above.
HEK293T cells Human embryonic kidney 293T cells (herein referred to as HEK cells)
were first established in 1973 in Alex van der Eb’s laboratory by transforming normal
human embryonic kidney cells with adenovirus 5 DNA (Graham et al., 1977). HEK293T
cells were received from the American Type Culture Collection (ATCC). HEK cells were
grown in the cell culture medium described above. The cells were cultivated in T-75 cell
culture flasks and spilt 1:10 every 3-4 days. HEK cells were used to produce retroviral
particles for transduction of primary cell cultures and for testing of produced viruses as
well as antibodies for immuno staining.
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DAOY cells DAOY (ATCC HTB-186) cells are an adherent cell line isolated from a
desmoplastic cerebellar medulloblastoma of a 4 year old Caucasian male established in
1985 by P. F. Jacobsen of the Royal Perth Hospital in Western Australia (Jacobsen et al.,
1985). At the time of characterisation, a genetic profile of the DAOY cell line was not
available. However, ”the Daoy MB cell line is derived from a desmoplastic MB [and has
since been shown] to exhibit global activation of SHH-pathway genes and is statistically
classified as SHH subgroup based on hierarchical clustering and PCA [pincipal component
analysis] with patient samples” (Liang et al., 2015). Cells were cultivated in the cell
culture medium described above and split three times a week. DAOY cells were used
for testing the effects of reintroducing WT TCF4 and different TCF4 mutants into a
SHH-associated medulloblastoma cell line.
7.2.3 Mouse experiments
All animal experiments were carried out in accordance with the Protection of Animal Act
and were approved by the Regierung von Oberbayern. Mice were housed in a SPF-animal
facility (specific-pathogen-free) in individually venitaled cages. The animal facility kept
a day and night rhythm of 12 to 12 hours. Water and food was available ad libitum.
For preparation of mice brains, adult mice were sacrificed via cervical dislocation, mice
younger than 14 days of age were sacrificed through decapitation.
7.2.3.1 Mouse strains
All mouse strains are listed in Section 7.1.7. For the mouse experiments, different trans-
genic mouse strains were used; these were SmoM2-YFPFl/F l (Mao et al., 2006), hGFAP-cre
(Zhuo et al., 2001), Math1-cre (Matei et al., 2005; Schu¨ller et al., 2007), Math1-creERT2
(Machold and Fishell, 2005), and Tcf4Fl/F l (Bergqvist et al., 2000). Additionally, the wild
type strains C57/Bl6 and FVB were used.
Conditional knockout mice An often used site-specific recombinase technology to
carry out deletions, translocations, inversions etc., is the Cre-Lox recombination. The Cre
recombinase is able to recombine DNA between specific sites, known as loxP sites, where
the Cre recombinase binds and catalyzes recombination (Sauer, 1987; Sauer and Hender-
son, 1988). Transgenic mouse strains carrying loxP sites can be mated with Cre-driverline
strains to create these conditional Cre-loxP-systems. Hence, the Cre recombinase can be
expressed under different promoters (here hGFAP and Math1 ) and initiate recombination
between the loxP sites in the DNA to cut out DNA sequences that lie within these sites.
Using different promoters, knockouts in specific tissues and cell lines can be created.
79
7. Material and Methods
Inducible knockout mice The oestrogen analogue tamoxifen can be used to induce
knockouts in mice by binding to a modified oestrogen receptor at any given point in time.
Transgenic mice carrying the genetic information for a fusion protein of the Cre recom-
binase and the oestrogen receptor are available (creERT2). Although the fusion protein
is expressed continuously in these mice, it is only able to enter the nucleus, which is
necessary for the Cre recombinase to initiate recombination, after treatment with tamox-
ifen. The time point of tamoxifen injection then defines the initiation of the respective
knockout. This fusion protein can be expressed under different promoters, additionally
creating tissue-specific knockouts, e.g. Math1-creERT2 (Feil et al., 1997; Helms et al.,
2000; Machold and Fishell, 2005).
7.2.3.2 Genotyping
For genoytping, mice tails from mice aged 3 days or ear dies from mice aged 21 days and
older were used. The tissue was digested in 500 µl of Laird’s lysis buffer and incubated
for at least 2 hours at 56 °C on a shaker. Afterwards, samples were centrifuged at
16,100 g for 5 min and the supernatant was transferred to a new tube containing 500 µl
of isopropanol. The tube with the suspension was shaken, causing the extracted DNA to
precipitate. The sample was centrifuged once more at 16,100 g for 5 min, the supernatant
discarded and the pellet dissolved in TE buffer and stored at 4 °C. The genomic DNA
could then be used for genotyping. PCR was used to amplify specific regions of the
DNA, distinguishing mutant and wild-type alleles.
All primer sequences used for PCR were taken from the original publications. Primers
were ordered from and synthesized by Eurofins. They were delivered as a lyophilisate
and had to be dissolved in ddH2O according to manufacturer’s specifications prior to
use. Primers were stored at -20 °C. For daily use, primers were diluted 1:10 (final
concentration of 10 µM) and stored at 4 °C. Primers and PCR cycling conditions are
listed in Tables 6 and 7.
The PCR mastermix was prepared as follows: For 10 samples, 2.5 µl of each, for-
ward and reverse, primer (concentration 10 µM) were mixed with 1.5 µl of 10 mM
dNTPs, 20 µl of 5× PCR buffer, 1 µl of Taq polymerase, and 62.5 µl of PCR water. The
solution was mixed and MgCl2 was added accordingly (see Table 6). For each sample,
9 µl of PCR mix and 1 µl of the respective DNA were mixed. PCR was carried out
depending on the gene of interest.
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Table 6: Primers used for genotyping and conditions for PCR. Primers are
given as fw (forward) and rv (reverse) primer in 5’ - 3’ direction. Noted are annealing
temperature and additional reagents for each PCR.
PCR Primer in 5’ - 3’ Conditions
TCF4 fw TGTGTATGTGCATATTTCCTTTATATTCC annealing 60 °C
rv AGATACCATGCGCAGAAATCTTT
CRE fw TCCGGGCTGCCACGACCAA 2 µl 25 mM MgCl2
rv GGCGCGGCAACACCATTTT in 100 µl sample,
annealing 65 °C
hGFAP fw ACTCCTTCATAAAGCCCTCG annealing 65 °C
rv ATCACTCGTTGCATCGACCG
SMO MUT fw GAACGGCATCAAGGTGAA annealing 60 °C
rv CGATGGGGGTGTTCTGCT
SMO WT fw GGAGCGGGAGAAATGGATATG 2 µl 25 mM MgCl2
rv CGTGATCTGCAACTCCAGTC in 100 µl sample,
annealing 65 °C
Table 7: PCR thermal cycler programmes used for genotyping.Given are the
different steps of each PCR according to annealing temperature and number of cycles.
Annealing 60 °C Annealing 65 °C
35 cycles 32 cycles
Heating-up 92 °C, 2 min 94 °C, 3 min
Denaturisation 92 °C, 30 s 94 °C, 30 s
Annealing 60 °C, 30 s 65 °C, 60 s
Elongation 72 °C, 60 s 72 °C, 60 s
Stop 4°C 4 °C
To verify PCR products, a gel electrophoresis was carried out. Products were loaded onto
a 1 % or 2 % agarose gel (150 ml TE buffer with 3 g agarose for a 2 % gel and 1.5 g
agarose for a 1 % gel were mixed and heated up in the microwave until transparent. 3 µl of
SybrGold were added). The chamber was set to 70 V for 90 min. A UV transilluminator
was used to visualize PCR products.
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7.2.3.3 Mouse weights
To examine whether a prenatal knockout of Tcf4 has effects on the growth of mice,
whole body weights, brain weights, and cerebrum and cerebellar weights separately of
hGFAPcre::Tcf4fl/fl, hGFAPcre::Tcf4fl/+, hGFAPcre::Tcf4+/+ mice were determined and
statistically analysed using t-tests. For whole body masses, mice were weighed every other
day until their death. Brain weights were determined on days P7, 14, and 21.
7.2.3.4 Tamoxifen treatment
Tamoxifen inducible mouse models were used to investigate the influence of a postnatal
Tcf4 knockout in a tumorous and non-tumorous environment. Through the injection of
tamoxifen in these transgenic mice, it is possible to activate the Cre recombinase postnat-
ally (see Section 7.2.3.1). In this project, the tamoxifen inducible mouse model Math1-
creERT2 was used, which makes it possible to specifically activate the Cre recombinase
postnatally at any chosen point in solely Math1 -positive cells. Mice were induced with
tamoxifen on day 5 through intra-peritoneal injection of 0.1 mg tamoxifen dissolved in
corn oil (25 µg per gramm body weight, i.e. 50 µl of 2 mg/ml solution).
7.2.3.5 BrdU pulse
For the investigation of proliferation rates of cerebellar granule cells in vivo, the different
mouse models were pulsed with BrdU and sacrificed two hours later. Mice received 25 µg
BrdU/g total body weight via an intra-peritoneal injection. BrdU is an analogue of the
nucleotide thymidine and is thus integrated into the DNA strand of proliferating cells.
Cells that incorporated BrdU, i.e. were proliferating during time of injection, could later
be visualised through the staining for BrdU. Therefore, mouse brains were embedded in
paraffin, stained for BrdU, and proliferation rates of the different layers of the cerebellum
were analyzed.
7.2.3.6 Tumour models in mice
Tumour models were used to determine the influence of Tcf4 knockouts on cell growth and
survival rates in SHH-associated medulloblastoma. Two different mouse models, hGFAP-
cre::Tcf4Fl/F lSmoM2-YFPFl/+ and Math1-creERT2Tcf4Fl/F lSmoM2-YFPFl/+, were in-
vestigated. Mice were examined daily by the staff of the animal facility to check for
symptoms and illness of mice. Mice were then either killed at a defined age for investiga-
tion of cell proliferation and apoptosis or sacrificed when symptoms became severe. These
data were used for analysis of survival rates.
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7.2.4 Histological methods
7.2.4.1 Embedded tissues
Preparation of tissues Tissues for staining with haematoxylin and eosin (H&E) and
other immunostaining were firstly stored in formaldehyde and later prepared and incub-
ated in 4 % PFA and PBS overnight and embedded in paraffin thereafter. The embedded
tissue was cut using a microtome, slices were of 5 µm, and the tissue was fixed to mi-
croscope slides. Paraffin was washed out using xylole and tissues were rehydrated with a
descending alcohol row. Tissues could then be stained. All pictures of embedded tissues
were taken with an Olympus Bx50 microscope using the ColorView Soft imaging system
(Olympus).
Immunohistochemistry General morphology of mice brains, specifically cerebella,
were observed using H&E stains of the paraffin embedded and cut tissue sections.
H&E staining was performed using standard protocols. The embedded slices were de-
paraffinated and rehydrated (xylole > 100 % ethanol > 95 % ethanol > 70 % ethanol >
ddH2O).
The slices were then cooked in citrate buffer (pH 6.0), five times for 4 min each, and cooled
down for antigen retrieval. For inactivation of endogenous peroxidase, slices were washed
in tab water and subsequently incubated in 5 % H2O2 in methanol (10 ml 30 % peroxide
in 50 ml methanol) for 20 min. The slices were again washed in tab water (5 min), ddH2O
(shortly) and PBS (5 min) before the blocking reagent I-Block (Invitrogen) was added for
30 min. The primary antibody was added (dilution in PBS, see Table 8) over night at
4 °C. The next day, slices were washed with PBS twice (5 min each) and the slices were
treated according to the System-HRP DAB-Kit protocol (Dako). Tissues were incubated
in the SE reagent for 20 min, washed twice with PBS, incubated in poly-HRP for 30 min,
washed with PBS and DAB (1 drop DAB in 1 ml DAB buffer) was added for 30 min.
The slices were then washed twice with ddH2O. In all the embedded tissues, nuclei were
counterstained using haemalum. Slices were incubated for 2 min in haemalum and then
directly blued in warm tab water for 10 min. In a last step, the slices were washed using
the alcohol row vice versa and the tissues were covered with cover slips.
83
7. Material and Methods
Table 8: Antibodies for immunohistochemistry (IHC) of embedded tissues.
Given are the antibodies for IHC, their dilution factor used and the manufacturer for
each antibody.
Antibody Dilution Manufacturer
anti-BrdU 1:500 Sigma
anti-CASP3 1:100 Cell Signaling Tech
anti-PAX6 1:50 DSHB
anti-PHH3 1:200 Cell Signaling Tech
anti-TCF4 1:25 Sigma
Analysis The H&E stains of mouse brains at different ages and with different genotypes
were compared. The different mouse brains were also stained for PAX6 to investigate the
formation of granule cells in the cerebella. Furthermore, stainings for CASP3 to compare
apoptosis rates and for pHH3 to compare mitosis rates were carried out. As described
above, mice received a BrdU pulse and hence, cell proliferation rates using BrdU staining
were determined as well. For the different stainings, cell numbers in the different layers
(EGL and IGL) were counted using ImageJ, compared between different age groups and
genotypes and tested for significance using chi-squared tests.
7.2.4.2 Cell cultures
Immunofluorescence For staining of cell cultures, cells had to be fixated first. There-
fore, the culture medium was aspirated and replaced with 300 µl of 4 % PFA for 30 min
at room temperature on the shaker. Then, cells were washed twice with PBS for 5 min
each, and washed again twice with PBS + 0.3 % Triton X-100 for 5 min each. The PBS
solution was discarded and 300 µl of 4N HCl was added for 10 min at RT on the shaker.
HCl was replaced with 300 µl of 0.1 M sodium borate buffer with a pH of 8.5 for 10 min.
Sodium borate was aspirated and 200 µl of blocking buffer (PBS + 0.3 % Triton X-100
+ 10 % Normal Goat Serum) were added and the 24-well plates were shaken at RT for
30 min. The blocking buffer was discarded and 200 µl of primary antibodies, for example
anti-GFP and anti-BrdU, in blocking buffer were added and incubated at 4 °C overnight
(see Table 9 for dilution). In a next step, primary antibodies were washed off with PBS
+ 0.3 % Triton X-100 three times and 200 µl of secondary antibodies, fluorophore-linked
antibodies (Alexa 488 and Alexa 546) targeting the primary antibodies, in blocking buffer
were added for 1 h at RT. Plates containing the cells had to be kept in darkness starting
with this step, i.e. plates were wrapped in aluminium foil. After incubation with the
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secondary antibodies, cells were washed twice with PBS + 0.3 % Triton X-100 and 500 µl
of 4’,6-diamidino-2-phenylindole (DAPI, 1:1000 diluted in PBS) for staining of nuclei was
added for 10 min at RT. Subsequently, cells were washed with PBS once and kept in 300 µl
of PBS thereafter. Fixated and stained cells were stored at 4 °C until analysis under the
fluorescence microscope (Olympus IX50) using the ColorView Soft imaging System.
Table 9: Antibodies for immunofluorescence (IF) of cell cultures and their
respective dilutions. Noted are the antibodies and their dilutions for IF, including manu-
facturer’s name. The antibodies are given as pairs as used in the IF of tissue cultures.
Antibody Dilution Manufacturer
anti-GFP (rabbit) 1:200 Santa Cruz
anti-BrdU (mouse) 1:500 Sigma
anti-TCF4 (rabbit) 1:500 Sigma
anti-GFP (mouse) 1:200 Invitrogen
anti-mouse (secondary) 1:500 Invitrogen
anti-rabbit (secondary) 1:500 Invitrogen
Analysis For the analysis of GCNP cultures, the fixated cells were stained for GFP
to determine cells that contained the Cre-IRES-GFP and the IRES-GFP plasmids
respectively; for BrdU, to see which cells were actively growing, and for DAPI to mark
cells. Cells were analyzed under a fluorescence microscope. Several hundred cells from
different fields of vision in five different experiments (n=5) were counted and the num-
bers of IRES-GFP and Cre-IRES-GFP positive cells from all BrdU+ cells were compared.
Analysis of DAOY cell cultures was done similarly. Cells were either stained for
GFP and TCF4 to determine if transduced cells were producing a functioning TCF4
protein. Additionally, cells were stained for GFP and BrdU to determine which of the
transduced cells were actively proliferating. GFP+/BrdU+ double-positive cells were
counted and the fraction of BrdU+ cells of all transduced cells was calculated and
compared to the growth rates of untreated cells.
7.2.5 Human data
For the mRNA expression profiles of human medulloblastoma, the open access database
R2 (R2: microarray analysis and visualization platform, http://r2.amc.nl) was searched.
A total of 464 samples of medulloblastoma, with 122 being SHH-associated medullo-
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blastoma were available. For 103 of these patients, not only expression profiles but also
survival data could be extracted. Since the data was made available by different research
groups, having used different sequencing technology, the data had to be normalised
before use. To unify gene expression measures, data from each batch were normalised
(standardised) and summarised separately resulting in gene expression estimates for
each sample and gene. Relative gene expression values were calculated using z-scores.
Normalisation was done by Dr. Julia Neumann.
In collaboration with the German Cancer Research Centre, a group of 133 samples with
secured pathological activation of the Sonic hedgehog signalling pathway was sequenced
and somatic mutations in TCF4 could be found in 14 % of cases (7/50) with adult SHH-
associated medulloblastoma (see Appendix Fig. 28, Kool et al., 2014).
7.2.6 Statistical analysis
All statistical analysis was carried out using the Prism 5.02 and Prism 7.01 software
(GraphPad). For the comparison of different groups (e.g. weights), all samples were
tested for Gaussian distribution first. In case of normal distribution, the groups were
compared using unpaired, two-tailed (Student’s) t-tests. If no Gaussian distribution
was found, a Mann-Whitney-U test was performed. Furthermore, chi-squared tests, a
qualitative test, were used to compare cell counts between different groups. For data of
patient and animal survival, Kaplan-Meier plots were drawn. Significance was calculated
using a logrank test. The level of significance for all statistical analysis was set to 5 %
(p<0.05). Standard deviation and mean were calculated for all data and plotted where
suitable. For all analysis, at least three samples/biological replicates (n=3) were used.
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Figure 26: TCF4 interaction network from Moen et al. (2017).6 Overview of
the protein interaction network in neural stem cells. FLAG-tagged transcriptional regulators
were purified and their interaction partners identified by mass spectrometry. TCF4 was one of
the tagged proteins. The interaction network illustrates the various proteins TCF4 interacts
with, many are associated with ID, schizophrenia, and autism-spectrum disorders. ”Red color
indicates network protein or protein complex subunit(s) encoded by a known ID gene. Orange,
yellow and blue color indicate de novo mutation(s) in patients with ASD-lowIQ, ASD-normIQ
and schizophrenia, respectively.” (Moen et al., 2017).
6”An interaction network of mental disorder proteins in neural stem cells” original from Moen et al.
(2017), Translational Psychiatry (Nature Publishing Group), part A from Fig. 1. Licensed under CC
BY 4.0 (https://creativecommons.org/licenses/by/4.0/).
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Figure 27: TCF4 mRNA levels in SHH MB and normal brain tissue in dif-
ferent age groups. All SHH MB age groups showed a significant difference in TCF4 mRNA
expression compared to fetal and adult cerebellum. Comparison within the SHH subgroups were
not significantly different. Relative gene expression values were calculated using z-scores. Values
on y-axis indicate number of standard deviation by which the value of the expression level is
different from the mean. Mean is shown as a bar for each group. Groups were compared with
each other using two-tailed t-tests and Mann-Whitney-U tests, respectively. n.s. = p> 0.05, **
= p< 0.01, *** = p<0.001, **** = p< 0.0001.
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Figure 28: Summary of sequencing data from Kool et al. (2014).7 Graphs (A-C)
summarize the mutations found in different genes for the three age groups separately. TCF4 is
encircled in red in the adult SHH MB group, showing that 14 % of tumours were found to have
a mutation.
Figure 29: Overview H&E stain of Math1-cre::Tcf4fl/fl mice at P22. Comparison
of cerebellar size shows that a homozygous knockout of Tcf4 causes cerebellar hypoplasia.
7Reprinted from Cancer Cell, 25(3), Marcel Kool, David T.W. Jones, Natalie Ja¨ger, Paul A. Northcott,
Trevor J. Pugh, Volker Hovestadt, Rosario M. Piro, L. Adriana Esparza, Shirley L. Markant, Marc
Remke, Till Milde, Franck Bourdeaut, Marina Ryzhova, Dominik Sturm, Elke Pfaff, Sebastian Stark et
al., Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened
Inhibition, 393-405, Copyright (2014), with permission from Elsevier.
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Figure 30: Apoptosis rates in hGFAP-cre::Tcf4fl/fl mice on P14. Cell counts of
CASP3+ cells in hGFAP-cre::Tcf4fl/fl mice and WT mice at P14 in lobulus V. A significant
higher number of CASP3+ cells occured after a homozygous knockout of Tcf4. Analysis was
done using an unpaired t-test. Error bars show mean + SD, *** = p<0.001.
Figure 31: MRI of a 19-months old girl with PTHS. T2 weighted image (left) and
T1 inversio recovery sequence (right) show a widening of the outer and inner CSF spaces, a
reduced volume of the subtentorial brain and a hypoplasia of the cerebellar hemispheres and
vermis. Furthermore, a slight disorganisation of the cerebellar folia can be seen. Pictures were
received with kind permission from Prof. Dr. Ertl-Wagner.
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Figure 32: Human TCF4 protein sequence. Protein sequence of isoform SEF-1B, also
known as TCF4-B− with a length of 667 amino acids. Sequence from UniProt (UniProtKB
- P15884 (ITF2 HUMAN), www.uniprot.org/uniprot/P15884). Antibody-binding domain of
anti-TCF4 (Sigma, HPA025958) is marked in green.
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ixTable 10: P-values for brain weights. Detailed list of all p-values calculated for comparison of brain weights on days P7, 14, and
21. P-values were calculated using two-tailed t-tests.
Genotypes Brain weight Cerebrum weight Cerebellar weight
P7 P14 P21 P7 P14 P21 P7 P14 P21
hGFAP-cre::Tcf4+/+
hGFAP-cre::Tcf4fl/+
0.9675 0.1989 0.0458 0.8439 0.3624 0.2995 0.2594 0.8788 0.42
hGFAP-cre::Tcf4+/+
hGFAP-cre::Tcf4fl/fl
0.1853 <0.0001 <0.0001 0.0112 <0.0001 0.0029 0.0023 0.0015 0.0075
hGFAPcre::Tcf4fl/+
hGFAP-cre::Tcf4fl/fl
0.1239 <0.0001 <0.0001 0.0109 0.0005 0.0015 0.0135 0.0016 0.0038
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